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Novel Antifolates to Target Antibiotic Resistant Gram-negative Pathogens 
Michael Nicolo Lombardo, PhD 
University of Connecticut, 2018 
 
Antibiotic resistance has limited our ability to treat life-threatening infections putting pressure on 
the scientific community to discover new effective therapeutics. There have been significant 
research efforts to develop drugs for the treatment of infections caused by Gram-negative 
pathogens as they are the leading cause of healthcare-associated infections and have a high 
propensity to accumulate antibiotic resistance genes. The two major challenges to Gram-negative 
antibiotic development are finding drug chemotypes that are able to penetrate the cell envelope 
and accounting for plasmid-associated resistance genes. We have developed a novel class of 
antifolates, designated as propargyl-linked antifolates, as effective antimicrobials against 
multidrug resistant Enterobacteriaceae, the leading cause of antibiotic resistant Gram-negative 
infections. Propargyl-linked antifolates are inhibitors of dihydrofolate reductase (DHFR) and 
derivatives of trimethoprim, a commonly prescribed DHFR inhibitor. Resistance to trimethoprim 
is conferred by a family of >30 naturally resistant DHFR and has limited its effectiveness. Through 
structure-based drug design, we have determined the mechanism by which propargyl-linked 
antifolates inhibit both trimethoprim-sensitive and resistant DHFR. In our design, we employed 
substrate-envelope constraints to expand the spectrum of activity of propargyl-linked antifolates 
such that they are potent inhibitors of multiple trimethoprim-resistant DHFRs. In all, these efforts 
have led to a comprehensive understanding of trimethoprim resistance and the development of 
inhibitors that overcome these mechanisms.  
  
i 
 
Novel Antifolates to Target Antibiotic Resistant Gram-negative Pathogens 
 
Michael Nicolo Lombardo 
 
 
B.S., University of Connecticut, 2009 
Pharm.D., University of Connecticut, 2011 
 
 
 
 
 
 
A Dissertation 
Submitted in Partial Fulfillment of the 
Requirements for the Degree of  
Doctor of Philosophy 
at the 
University of Connecticut  
 
2018 
 
ii 
 
 
Copyright by 
Michael Nicolo Lombardo 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2018 
 
iii 
 
APPROVAL PAGE 
 
Doctor of Philosophy Dissertation 
 
Novel Antifolates to Target Antibiotic Resistant Gram-negative Pathogens 
 
 
 
 
Presented by 
Michael Nicolo Lombardo, B.S., Pharm.D. 
 
Major Advisor 
___________________________________________________________________ 
     Dennis L. Wright 
 
Associate Advisor 
___________________________________________________________________ 
     Victoria L. Robinson 
 
Associate Advisor 
___________________________________________________________________ 
     José Manautou 
 
 
 
 
University of Connecticut 
2018 
 
iv 
 
 
 
 
 
 
 
This dissertation is dedicated to my family and friends. 
I would not be where I am without the unconditional love and support of my parents, Nick and 
Cheryl, my sister, Nicole, and brother-in-law, Graeme. I am forever grateful for the lifelong 
friends I have made throughout my time at UConn. 
 
In memory of Amy Anderson whose dedication and passion for science brought me to research 
and continues to inspire me. 
 
  
v 
 
Table of Contents 
 
Chapter 1 Antibiotics, Resistance and the Need for Novel Therapeutics 1 
1.1 Mechanisms of Antibiotic Resistance 3 
1.2 Strategies to combat resistance 5 
1.2a Understanding Efflux Mechanisms and Specificity 7 
1.2b β-lactams and Drug Design to Overcome Drug Modifying Enzymes 11 
1.2c Fluoroquinolone and Overcoming Spontaneous Mutational Resistance 12 
1.3 The Folate Pathway and Clinical Antifolates 14 
1.4 The Discovery and Development of Propargyl-linked Antifolates 19 
1.5 References 22 
Chapter 2 Crystal structures reveal propargyl-linked antifolates bind E. coli dihydrofolate 
reductase to form a novel, highly stable inhibitory complex 32 
2.1 Introduction 32 
2.2 Results and Discussion 34 
2.2a Four crystal structures of E. coli DHFR:PLAs reveal the occluded conformation 34 
2.2b Assessing the novelty of PLA interactions 42 
2.2c Preferential inhibition of the closed or occluded conformation 43 
2.3 Conclusion 48 
2.4 Supplemental Tables & Figures 50 
2.5 References 54 
Chapter 3 Crystal structures of trimethoprim-resistant DfrA1 rationalize potent inhibition by 
propargyl-linked antifolates 58 
3.1 Introduction 58 
3.2 Results and Discussion 60 
3.2a PLAs are Effective Antibacterial Agents for Enterobacteriaceae 60 
3.2b Analysis of the DfrA1 enzyme 63 
3.2c Propargyl-linked Antifolates are Active against the A1 Enzyme 64 
3.2d Crystal structure of DfrA1 65 
3.3 Conclusions 68 
3.4 Supplemental Tables & Figures 70 
3.5 References 72 
vi 
 
Chapter 4 Structural analysis of trimethoprim-resistant DfrA enzymes leads to multi-targeting 
propargyl-linked antifolates 76 
4.1 Introduction 76 
4.2 Results 80 
4.2a Primary sequence analysis of DfrA enzymes 80 
4.2b Biochemical characterization of E. coli DHFR, DfrA1, DfrA5, DfrA12 and DfrA17 84 
4.2c Crystal structures of E. coli DHFR, DfrA1 and DfrA5 85 
4.2d Propargyl-linked inhibition of E. coli DHFR, DfrA1 and DfrA5 91 
4.3 Discussion 94 
4.3a Insights to enzyme catalysis: Comparison of E. coli DHFR and DfrA5 94 
4.3b Insights to trimethoprim resistance: DfrA5 97 
4.3c Propargyl-linked antifolate  inhibition of E. coli DHFR, DfrA1, and DfrA5 97 
4.4 Conclusions 107 
4.5 Supplemental Tables & Figures 109 
4.6 References 116 
Appendix A Materials & Methods 122 
1 
 
Chapter 1 Antibiotics, Resistance and the Need for Novel Therapeutics 
 
Antibiotic resistance often prevents the successful treatment of bacterial infections. The Centers 
for Disease Control [1] estimates that over 2 million people annually contract an antibiotic resistant 
infection [2]. While this will be the direct cause of death for 23,000 patients, many more die from 
complications of the disease [2]. Metrics commonly used to describe the burden of antibiotic 
resistance, such as morbidity, mortality, length of hospital stay, and cost of care, indicate there is 
a negative effect on public health; yet they insufficiently describe the true social and economic 
costs. 
 
The World Health Organization (WHO) found that patient outcomes depend on whether an 
infection is antibiotic resistant or sensitive [2]. Escherichia coli, Klebsiella pneumoniae, and 
Staphylococcus aureus cause over 35% of healthcare associated infections and are most often 
associated with antibiotic resistance; in many clinical settings, resistance rates exceed 50% [2]. 
A systematic review of the literature showed that patients with a multidrug-resistant E. coli 
infection not only are twice as likely to be admitted to an intensive care unit (ICU) due to infection 
but also have a two-fold increased risk of all-cause mortality, infection-attributed mortality and 30-
day mortality when compared to those with an antibiotic-sensitive E. coli infection [2]. Similar 
trends in morbidity and mortality were seen when comparing sensitive and resistant K. 
pneumoniae and S. aureus infections; however, there was also a significant increase in ICU 
length of stay, hospital length of stay, and discharge to a long-term care facility associated with 
these infections [2]. The inability to treat these infections has had an economic impact costing the 
United States healthcare system over $34 billion annually [3]. 
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In 2013, the CDC label multidrug resistant Enterobacteriaceae, the family of Gram-negative 
bacteria that includes Klebsiella pneumoniae and Escherichia coli as urgent threats to human 
health [1]. The highest threat level, urgent antibiotic resistant threats have high transmissibility 
leading to an alarming 10-year incidence projection [1]. With limited availability of effective 
antibiotics, these threats require urgent public health attention to address their clinic and 
economic impact. The rapid emergence of ESBL-producing and carbapenemase-producing 
Enterobacteriaceae (CRE), highlighted by the rapid dissemination of the New Delhi metallo-β-
lactamase-1 type, illustrates the severity of the resistance epidemic. CRE by definition carry 
genes for β-lactamases, enzymes that inactivate all classes of β-lactams, which are considered 
the strongest antibiotics available. However, the threat caused by CRE is elevated as the genes 
encoding carbapenemases and ESBLs are often found on mobile genetic elements with 
resistance genes to all available antibiotics. Mortality rates for patients who contract CRE 
infections has been reported as high as 52% [4]. The threat posed by multidrug resistant 
Enterobacteriaceae was reiterated by the WHO citing it as a global problem highlighted by an 
antibiotic discovery void spanning 30 years. 
 
Antibiotic resistance is caused by two related factors: the excessive use of antibiotics and the 
genetic diversity of bacteria [5]. Unnecessary exposure of bacteria to antibiotics selects for 
antibiotic resistant phenotypes. While antibiotic use as a growth promoter in livestock, in some 
countries this accounts for 50-80% of total antibiotic use, prescribing practices are a significant 
contribution to the development of resistance [6-7]. Practitioners frequently prescribe antibiotics 
prior to consulting diagnostic cultures with the intention of reducing infection time; however, this 
often results in inappropriate antibiotic selection and unnecessary rounds of antibiotic therapy [5]. 
Additionally, antibiotics are administered at predetermined doses and durations according to FDA 
approved package insert guidelines. It is now realized that using empirical dosing strategies does 
not affect infection relapse and rather can promote the development of resistance [5] [8]. 
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1.1 Mechanisms of Antibiotic Resistance 
Resistance to every class of antibiotics has been identified in the clinic. The resistance 
mechanisms that affect antibiotics can be categorized as intrinsic, acquired or adaptive. Intrinsic 
resistance, referring to inherent traits characteristic to a species of bacteria, has hindered the 
development of new therapies. For example, Gram-negative bacteria are inherently resistant to 
vancomycin because the drug cannot cross the outer membrane [10]. K. pneumoniae displays 
innate ampicillin resistance to because of beta lactamase production [10]. Adaptive resistance is 
a temporary response, such as up-regulation of genes or expression of proteins that allows the 
bacteria to persist in the presence of environmental changes including nutrition deprivation or 
sub-inhibitory levels of antibiotics [11]. While intrinsic and adaptive resistance primarily affects the 
discovery of novel antibiotics, acquired resistance reduces the effectiveness of current 
therapeutics. Bacteria can acquire resistance through accumulation of spontaneous mutations in 
chromosomally located genes or through the horizontal transfer of plasmid-encoded resistance 
elements. Resistance genes can also be acquired from either the same or different species [10]. 
Mechanisms of horizontal gene transfer include transduction, transformation and conjugation. 
Vectors carrying resistance genes may be plasmids, transposons or integrons [10]. 
 
Bacteria can acquire resistance through mutations in DNA that either reduce the drug’s ability to 
inhibit the target or induce expression of intrinsic mechanisms (e.g. over expression of target 
enzyme, efflux pumps or beta-lactamases) [10]. Mutations in a target protein can reduce the 
drug’s affinity for the enzyme either directly, through the loss of binding site interactions, or 
indirectly, through distal mutations that change the conformation or dynamics of the binding site 
[12]. Fluoroquinolones, often used to treat respiratory and urinary tract infections, work by 
inhibiting DNA gyrase and topoisomerase IV, enzymes involved in DNA replication. DNA gyrase 
and topoisomerase IV work in tandem to break and re-ligate DNA strands throughout the 
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replication process. The GyrA subunit of DNA gyrase and the ParC/GrlA subunit of topoisomerase 
IV bind DNA while the GyrB and ParE/GrlB subunits bind ATP and facilitate hydrolysis of the 
phosphodiester DNA bond. Fluoroquinolones bind to the DNA interface of GyrA and ParC/GrlA 
leading to accumulation of DNA strand breaks. The majority of clinical resistance to 
fluoroquinolones is caused by the stepwise accumulation of mutations in the ‘quinolone resistance 
determining region’ (QRDR) of GyrA and ParC/GrlA. In Gram-negative bacteria, mutations first 
accumulate in GyrA; however, high fluoroquinolone resistance is associated with multiple QRDR 
mutations. 
 
Although Gram-negative bacteria can exhibit innate antibiotic resistance as well as develop 
resistance through genetic mutations, the acquisition of plasmid-associated resistance genes has 
had the most clinical impact. Plasmid acquired resistance genes are a particularly effective 
mechanism of antibiotic resistance as it allows rapid dissemination without a significant fitness 
cost to the bacteria [13]. Additionally, plasmids often carry multiple resistant genes to multiple 
antibiotics. The true clinical significance of plasmid-associated dissemination of antibiotic 
resistance genes was realized in 2016, when the first pan-resistant strain of bacteria was 
documented in the United States [14]. The clinical isolate, E. coli MRSN 388634, was cultured 
from the urine sample of a 49 year-old patient from Pennsylvania carrying two plasmids containing 
15 antibiotic resistance genes including the colistin resistance gene, mcr-1 [14]. Colistin, a 
nephrotoxic last-line therapy, was the last antibiotic with no clinically observed resistance. 
Genes harbored on plasmids encode drug-resistant enzyme variants have rendered all classes 
of antibiotics ineffective. These enzymes can work through a variety of mechanisms including 
drug or target modification or introduction of an innately resistant drug target.  
 
While there are several mechanisms of resistance to β-lactam antibiotics, drug-inactivation via β-
lactamases is by far the most common and most important [76]. β-lactamases break the β-lactam 
5 
 
ring open through hydrolysis and subsequently deactivate all antibacterial properties. With over 
1,600 β-lactamases identified, they are classified into four groups depending on structure and 
function [76]. Class A, B and D β-lactamases all utilize a nucleophilic serine; however, Class D 
OXA β-lactamases, despite being highly heterogeneous with over 500 serine-based β-
lactamases, have a fundamentally different mechanism of hydrolysis [76]. Class C β-lactamases 
consist of metallo-β-lactamase inactivate β-lactams through a Zn2+-mediated noncovalent 
mechanism [76]. 
 
Genes for target modifying enzymes classically affect antibiotics that inhibit the bacterial 
ribosome, particularly aminoglycosides and tetracyclines. Tetracycline, a broad-spectrum 
antibiotic, targets the 16S subunit of the ribosome where aminoglycosides have a primary binding 
site on the 30S subunit [74-75]. In both cases, a significant amount of clinical resistance is 
conferred through modification of the ribosome [74-75]. The target modifying enzymes are 
classified based on the type of modification they carry out. Considered either acetyltransferases, 
nucleotidyltransferases or phosphotransferase, these enzymes chemically add functional groups 
that sterically block inhibitor binding without affecting the ribosomal function [74]. 
 
1.2 Strategies to combat resistance 
To curtail antibiotic resistance, there has been a strong push to adjust the how antibiotics are 
used. Antibiotic stewardship programs have been developed and implemented to teach 
physicians better prescribing techniques. Antibiotic stewardship aims to limit inappropriate 
antibiotic use; primarily, ensuring the proper selection of the antibiotic (including dose and 
administration) and whether one is needed [15]. Improving awareness and antibiotic stewardship 
have had a significant impact in slowing the rate of resistance. Antibiotic stewardship programs 
have reduced antibiotic resistant infections and patient colonization with multidrug resistant 
bacteria by 42% [16]. 
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Preservation of current antibiotics can be attained through the optimization of antibiotic dosing 
and administration to achieve the best results and reduce resistance [17]. Antibiotics enact 
antibacterial activity either by achieving the highest possible drug concentration at the site of 
infection or by maximizing the duration that plasma levels are maintained above the minimum 
inhibitory concentration (MIC).  Fluoroquinolones, for example, require the concentration of free 
drug to be at least 125 times higher than the MIC [17]. Levofloxacin, a common therapy for 
pneumoniae, is often dosed at 500mg daily, which translates to a tissue AUC of 25.5 mg/L [18]. 
The clinical breakpoint for resistance of levofloxacin is 17 mg/L [18]. As a result, an infection with 
a strain of E. coli defined as susceptible could be treated with a suboptimal dose of levofloxacin 
and promote the selection of resistance. 
 
Efficient use of antibiotics and intensive infection control has had positive effects on slowing the 
spread of resistance and preserving the antibiotics currently approved; however, outbreaks are 
only reduced. Only the development of new therapies will effectively stop outbreaks of drug-
resistant infections. Overcoming resistance to existing antibiotics often involves the iterative 
optimization of a first-generation therapeutic to guide the design of second-generation compounds 
that are effective against the resistant organism. To achieve this, each generation of compound 
must undergo expensive development and evaluation.   An alternative approach, addressed in 
this thesis, focuses on incorporating and overcoming potential resistance early in the development 
cycle, ideally resulting in a first-generation drug that is less susceptible to resistance.  During this 
drug development process, potential resistance mechanisms would be identified and its 
mechanisms studied. This would allow for the design of improved candidates before introduction 
to clinical trials. This strategy of using structural models of resistance mechanisms has been 
particularly effective in other clinical indications with examples such as the development of HIV 
protease and reverse transcriptase inhibitors as well as several tyrosine kinase inhibitors [19, 20, 
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21, 22]. Currently, only efflux, enzymatic modification and target mutations can be modeled at this 
time, mostly owing to the determination of critical crystal structures of efflux pumps, drug-
modifying enzymes and modified targets.   
 
1.2a Understanding Efflux Mechanisms and Specificity  
Efflux is the active removal of antibiotics via a protein pump from the bacterial cell. While the direct 
decrease in intracellular drug concentration contributes to resistance on its own, efflux also 
provides bacteria time to accumulate mutations in other drug targets to increase resistance; this 
sequence is known to occur with fluoroquinolones [23]. Genes encoding efflux pumps are either 
located on the chromosome or acquired through plasmid transmission. It is believed that the over-
expression of efflux pumps is among one of the first steps in the development of antibiotic 
resistance; however, native expression levels can confer resistance to both single agents as well 
as entire classes of antibiotics. Narrow spectrum efflux pumps have one specific substrate (e.g. 
tetracycline) whereas broad-spectrum pumps can bind and export multiple substrates. To date, 
there have been five families of chromosomally encoded efflux pumps identified, four of which 
have been determined to be clinically relevant: the resistance nodulation division (RND) family, 
the major facilitator superfamily (MFS), the staphylococcal multi-resistance (SMR) family, and the 
multidrug and toxic compound extrusion families. Clinically relevant efflux pumps are found in 
both Gram-positive, Gram-negative and mycobacterial pathogens [23, 24]. 
 
The majority of efflux pump families utilize a common mechanism in which the pump transports 
antibiotics from the cytoplasm to the periplasm using a transmembrane proton gradient. Efflux 
pumps of the RND family have been of particular interest because of their ability to transport drugs 
directly to the external medium from the cytoplasm [24]. The RND pumps are comprised of three 
components: 1) a transporter protein, 2) a periplasmic accessory protein, and 3) an outer 
membrane protein channel. One of the more well studied RND pumps is the AcrAB-TolC complex 
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found in E. coli. Crystal structures reveal that AcrA, the periplasmic protein, coordinates the 
linkage of AcrB, the transporter protein, with TolC, the outer membrane channel [24]. Structures 
suggest that substrates bind a pocket at the surface of AcrB and are then transported to a deeper 
(distal) pocket near the periplasmic domain before being funneled to the TolC unit (Figure 1.1). 
Lipophilic substrates can diffuse towards the pockets where they bind to the wall of AcrB and are 
pumped out with the proton gradient. 
 
Figure 1.1. a) AcrB shown with the transmembrane, transporter and TolC docking domains 
shown (PDB ID 2DRD). Minocycline is shown in blue, the residues observed from in the distal 
pocket that interact with substrates are shown in magenta and the residues observed to 
interact with inhibitors shown in orange. The residues of the surface pocket overlap with the 
residues that interact with inhibitors. b) an expanded view of the residues that interact with 
substrates (magenta) and inhibitors (orange). For clarity, the view in B is rotated 180° from 
that shown in A. 
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There has been strong motivation to overcome or avoid resistance by efflux during the antibiotic 
development phase. These efforts have primarily focused on two strategies I) the design of 
antibiotics that are not substrates of efflux pumps  and II) the development of efflux pump inhibitors 
for co-administration with antibiotic substrates. Toward the first goal, co-crystallization of AcrB 
with various ligands has led to the hypothesis that the cavity of AcrB is filled with a lipid bilayer 
that is confluent with the inner membrane [25]. This requires substrate binding with both protein 
residues as well as interactions with phospholipids, allowing  pumps to bind compounds based 
on charge and lipophilicity where positively charged ligands are bound using the head groups of 
negatively charged phospholipids.  For example, fluoroquinolones behave as amphiphilic cations 
that bind the phospholipid and then diffuse to the central cavity for transport [23]. Likewise, beta-
lactam antibiotics with lipophilic side chains are known to be good substrates of AcrB as they are 
expected to partition partially in the bilayer with the carboxylate groups exposed to the solvent 
[23]. The flexibility of the AcrB complex explains the wide range of substrates but does not 
necessarily provide a solution to avoiding the potential for novel antibiotics to be substrates of the 
pump. 
 
Overall, there has been only preliminary advancement in the determination of structure-efflux 
activity relationships mostly owing to the vast diversity of substrates and lack of detailed 
understanding of substrate binding. Site-directed mutagenesis of residues near ligands observed 
in crystal structures has identified residues essential to AcrB activity [24]. Additionally, molecular 
dynamics studies investigating the binding of several known substrates and two inhibitors have 
shown that known substrates bind the distal pocket, making specific interactions with hydrophobic 
residues Phe 178, Ile 277, Val 612 and Phe 615 [25]. Interestingly, simulations of two known 
inhibitors show that the compounds dock outside the distal pocket, possibly preventing the 
movement of substrates from the surface to the distal pocket. Although these studies are just 
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getting underway, these detailed investigations of substrate and inhibitor binding sites should aid 
the development of new antibiotics that avoid efflux as well as novel efflux pump inhibitors (EPI). 
 
The majority of EPIs that have been explored immobilize the G-loop of AcrAB that is responsible 
for ushering substrates from the surface pocket to the distal pocket. EPIs that have this 
mechanism of action are generally structurally similar to the peptidomimetic, PAβN, but have not 
been used clinically owing to some toxicity issues. MBX2319, a novel pyranopyridine, is thought 
to inhibit AcrB via binding at the interface between the surface pocket and distal pocket [24]. 
Molecular dynamic simulations suggest that a cluster of phenylalanines plays an important role in 
inhibitor binding [24]. This is supported by recently published crystal structures of AcrAB bound 
with pryridopyrimidine EPI derivatives [26]. MBX2319 shows specificity towards AcrB but has 
activity over a range of organisms and demonstrates the ability to potentiate the activity of 
fluoroquinolones in bacterial strains overexpressing efflux pumps by up to 8- fold [27]. 
 
Figure 1.2. a) Beta-lactam antibiotic structures and imipenem, the first clinically available 
carbapenem antibiotic. Crystal structures of imipenem bound to b) TEM-1 (PDB: 1BT5, 
magenta) and c) AmpC (PDB: 1LL5, blue) beta-lactamases. 
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1.2b β-lactams and Drug Design to Overcome Drug Modifying Enzymes 
β-lactam antibiotics, including penicillins, cephalosporins and carbapenems (Figure 1.2), exhibit 
a broad spectrum of activity and are often used as first line therapies for many Gram-negative 
and Gram-positive therapies. However, β-lactam resistance, conferred primarily through drug 
deactivation via β-lactamases, have become a major barrier to effective treatment. β-lactam 
antibiotics target the transpeptidase domain of penicillin binding proteins (PBPs) involved in 
bacterial cell wall synthesis. PBPs are essential to bacterial survival and the maintenance of cell 
wall integrity by acting as transpeptidases, cross-linking adjacent glycan strands in the cell 
membrane. The β-lactam ring, the defining characteristic of this class of antibiotics, mimics the 
geometry of the D-alanine-D-alanine linkages of the glycan strands and is the basis for affinity of 
these antibiotics towards the PBPs [28]. β-lactamases recognize the β-lactam pharmacophore 
and deactivate the drug via hydrolysis. 
 
The prevalence of chromosomal and plasmid-acquired β-lactamases has diminished the efficacy 
of many β-lactam antibiotics [28]. There are four different classes of β-lactamases based on 
structural homology. Classes A, C and D β-lactamases employ a nucleophilic serine to acylate 
the β-lactam bond while Class B uses a Zn2+ ion in the active site [29].  As β-lactamases have a 
high degree of structural homology to the PBPs, β-lactam antibiotics exhibit high affinity for these 
enzymes. Beta-lactams bind Class A β-lactamases and the nucleophilic active site serine acylates 
the carboxylate on the β-lactam ring via a ring opening reaction [30]. Once acylated, an active 
site water molecule hydrolyzes the acyl bond and the cleaved, deactivated β-lactam antibiotic is 
released from the active site [30]. Extended-spectrum β-lactamases (ESBLs), mainly from Class 
A, arose from early β-lactam use and are active in certain Gram-negative bacteria. ESBLs 
inactivate cephalosporin antibiotics that are typically resistant to acylation via β-lactamases [30].   
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Among the β-lactam antibiotics that are not susceptible to deactivation by serine β-lactamases 
(Class A, C and D) is a class of antibiotics called carbapenems. Structurally, carbapenems have 
a similar 4-5 fused ring scaffold as penicillins differing by carbon substitution at the C1 position 
and a double bond at the C2-C3 position of the pyrroline ring (Figure 1.2). Of the clinically relevant 
β-lactams, carbapenems have the greatest potency and broadest spectrum of activity towards 
Gram-negative and Gram-positive bacteria [28]. Carbapenems act as β-lactamase inhibitors and 
are inherently resistant to deactivation by β-lactamases. Imipenem, the first clinically available 
carbapenem, binds the β-lactamase active site with high affinity and like other β-lactam antibiotics 
becomes acylated. However, owing to a slow rate of hydrolysis, imipenem acts as an inhibitor 
instead of a substrate. A crystal structure of imipenem bound to TEM-1, a Class A β-lactamase 
(PDB: 1BT5) and AmpC, a Class C β-lactamase (PDB:1LL5) captures the acyl intermediate that 
is key to its action as a β-lactamase inhibitor (Figure 1.2).  The structures show the 6α-1R-
hydroxyethyl substitutions on the β-lactam ring cause the ligand to adopt an unexpected, strained 
conformation displacing the hydrolytic water in the active site, protecting it from deacylation [30, 
31].  
 
Discovery of newer generation carbapenems is critical in order to overcome emerging resistance 
by Class B beta-lactamases and the metabolic instability of imipenem. Imipenem is susceptible 
to elimination via dehydropeptidase-1 (DHP-1) found in the renal tubules, requiring the co-
administration of a DHP-1 inhibitor to improve stability. Doripenem, a later generation 
carbapenem, corrects for imipenem’s metabolic instability, increases its Gram-negative bacterial 
activity and has reduced β-lactamase susceptibility [32].  
 
1.2c Fluoroquinolone and Overcoming Spontaneous Mutational Resistance  
Mutational resistance in response to antibiotic pressure can quickly confer high levels of 
resistance during the course of clinical care. Mutations in the active site of the target enzyme can 
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effective in reducing affinity of the drug. It is possible to determine the structures of both the wild 
type and mutated (resistant) proteins in order to understand the basis of resistance, thus enabling 
a modeling approach to predicting and overcoming the loss of interactions. The primary 
mechanism of resistance to fluoroquinolones is a stepwise accumulation of mutations in TopoIV 
and gyrase, many of which are in the “quinolone resistance determining region” (QRDR) in the 
GyrA subunit. High levels of resistance are often achieved through mutations in the target 
combined with upregulation of efflux pump activity, for example norA in S. aureus. Crystal 
structures of Acinetobacter baumannii or Streptococcus pneumoniae ParC/E bound to DNA and 
moxifloxacin have revealed many of the details of the mechanisms of topoisomerases, the mode 
of inhibition of the quinolone antibiotics and the structural basis of quinolone resistance [33, 34].  
 
 
Figure 1.3. a) chemical structures of moxifloxacin and GSK299423 b) the 
crystal structure of gyrase (purple) bound to DNA (backbone shown in 
orange) and two copies of GSK299423 (cyan) from PDB ID: 2XCS [23]. 
The figure shows a superposition of moxifloxacin (green) from PDB ID: 
3FOF [22]. Typical resistance mutations are shown in magenta. 
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In response to the observed resistance to quinolones, several groups have worked to design more 
effective molecules that are active against the resistant strains. For example, scientists at Glaxo 
Smith Kline designed compound GSK299423 to act via a mechanism distinct from the quinolones 
based on stabilization of a pre-cleavage enzyme-DNA complex [35]. Structures of GSK299423 
show that the compound occupies a novel non-catalytic binding pocket between the two GyrA 
subunits, which is adjacent to but not overlapping with the ciprofloxacin site (Figure 1.3). As such, 
the affinity of the compound is not affected by the existing resistance mutations. In fact, 
GSK299423 shows potent activity against several bacterial strains, both wild-type and 
fluoroquinolone-resistant. 
 
1.3 The Folate Pathway and Clinical Antifolates 
With the increasing need for new antibiotics, the folate pathway represents an underutilized target 
despite pathway clinically proven effectiveness. The folate pathway is the primary source of 
deoxythymidine monophosphate, purine nucleotides, and amino acids, metabolites required for 
cellular functions like DNA replication and repair making it an attractive therapeutic target for 
diseases dependent on rapidly dividing cells, including cancer and infectious disease. There are 
several potential therapeutic targets; however, dihydrofolate reductase (DHFR) and 
dihydropteroate synthase are currently the only enzymes exploited for antibacterial activity [37]. 
DHFR represents a critical node in the pathway and while it is found in both the eukaryotic and 
prokaryotic organisms, it has structure differences that allow for selective inhibitors of bacterial 
enzymes. Unlike other classes of antibiotics, there are no second-generation derivatives of 
trimethoprim and it remains the lone antibacterial DHFR inhibitor. 
 
In both prokaryotes and eukaryotes, tetrahydrofolate and N5,N10-methyl tetrahydrofolate serve as 
the one carbon donor or acceptor in folate pathway reactions. Where many eukaryotes, including 
humans, acquire folate from the environment, prokaryotic folate pathway begins with folate 
15 
 
synthesis (Figure 1.4). Formation of the pterin ring from GTP by GTP cyclohydrolase I is the first 
committed step in folate biosynthesis. Following a series of aldolase and kinase steps, the 
resulting 6-hydroxymethyl-7,8-dihydropterin is converted to dihydropteroate with the addition of 
para-benzoic acid by dihydropteroate synthase. In the final folate biosynthesis step, dihydrofolate 
synthase adds a glutamate moiety to dihydropteroate to give dihydrofolate (aka folic acid). DHFR 
then reduces DHF to THF via oxidation of NADPH. THF goes on to serve as an intermediate 
carrier of single carbons in various reactions involved in de novo purine synthesis and the 
serine/glycine metabolism (or various biosynthetic/degradation reactions. A major reaction THF 
undergoes is the cyclization to N5,N10-methylTHF by Serine hydroxymethyltransferase, which is 
used primarily in methionine synthesis or converted back to DHF by thymidylate synthase [37].  
 
DHFR plays a central role in the folate pathway and links the divergent mechanisms of either 
folate synthesis by prokaryotes or acquisition from the environment from prokaryotes. The 
downstream reactions are widely conserved, many of which are redundant or conserved [37]. Not 
only is the product of DHFR essential for several cellular processes but DHFR is the only source 
of THF for the cell. Inhibition of DHFR prevents DNA and protein biosynthesis halting cell 
proliferation. 
 
The important role DHFR plays in cellular processes has led to several biological studies with 
nearly 250 3D structures published in the Protein Data Bank. Although its sequence homology is 
low across species, the structure and function of DHFR is highly conserved [38]. The 
characteristic ternary structure of DHFR consists of an eight-stranded Beta-sheet with four 
neighboring alpha helices. The enzyme reduces DHFR to THF by catalyzing hydrate transfer from 
cofactor NADPH to the C6 of DHF with the coinciding protonation of N5 [38]. Positioning of DHF 
in the active site relies on a conserved Asp or Glu; mutational studies have shown the ionizability 
of this residue is critical for the reaction to take place [39]. 
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Figure 1.4. The folate path; enzymes are in bold and end products (dTMP, amino acids and 
nucleotides) are boxed. Synthesis of 6-hydroxymethyl-7,8-dihydropterin from GTP is not 
shown.
 
17 
 
E. coli DHFR, an 18-kDa protein consisting of 161 amino acids, has been extensively described 
[9]. Unique to E. coli DHFR, a large conformational shift occurs as the enzyme cycles through five 
distinct kinetic intermediates [9, 38]. Initiation of the reaction occurs with formation of the Michalis 
complex (enzyme:substrate:cofactor). Hydride transfer occurs preceded by the release of 
oxidized cofactor. Only when new cofactor is bound, is product released and allow new substrate 
to bind. Crystal structures show residues 9-24 of the Met 20 loop are responsible for expelling 
oxidized cofactor and facilitating NADPH rebinding [38]. NMR studies confirm this shift occurs in 
solution and is not a product of crystallization conditions [40]. As such, the rate-limiting step is 
NADPH rebinding [40]. Despite a detailed understanding of the structural mechanism of E. coli 
DHFR, there are limited DHFR inhibitors available for the treatment of infectious diseases. 
 
Targeting DHFR is a widely successful treatment strategy for several disease states in addition 
to bacterial infections. Methotrexate and pemetrexed have multiple oncological indications.  
While they potently inhibit bacterial DHFR, methotrexate inhibits E. coli DHFR in the nanomolar 
range; the compounds themselves carry a strong negative charge and require active transport 
into cells, a mechanism exclusive to eukaryotic systems. Pyrimethamine and proguanil are 
commonly used in the treatment of parasitic infections but do not have activity against bacterial 
pathogens. Trimethoprim remains the lone clinical DHFR inhibitor used for bacterial infections.   
 
Resistance to trimethoprim can occur through five major mechanisms of resistance including 
reduced permeability or efflux, overexpression of DHFR, natural insensitivity due to endogenous 
DHFR isoform, acquisition of insensitive DHFR enzymes from innately resistant species and the 
accumulation of point mutations in DHFR gene [41]. These mechanisms do not occur in every 
species. Efflux pumps impart innate resistance to trimethoprim in Pseudomonas aeruginosa while 
Bacteriodes spp., Neisseria spp. and Moraxella catarrhalis have innately resistant chromosomal 
DHFRs. Acquired resistance manifests in both gram-positive and gram-negative specie of 
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bacteria through either spontaneous SNPs that result in mutant DHFR and overexpression of 
plasmid-associated resistant DHFR enzymes [41]. Trimethoprim resistance in 
Enterobacteriaceae is frequently conferred by the acquisition of plasmid-associated DHFR but in 
rare instances have been attributed to point mutations that cause overexpression of chromosomal 
DHFR and point mutations that result in lower affinity for the enzyme. 
 
Two structurally distinct families of plasmid-borne DHFR, DfrA and DfrB,  have been attributed to 
clinical failure of trimethoprim in Gram-negative pathogens The DfrA family have the characteristic 
fold of DHFR, eight-strand β-sheet with four flanking α-helices. The DfrB family of DHFR are 
homotetramers, with each monomer having five antiparallel beta-strands that assemble into a 
dimer with a six-strand beta-barrel [42]. Only seven DfrB enzymes have been identified, with 
DfrB1 (aka R67) being the most common [42]. They are largely inefficient as DHFRs largely owing 
to their structure [42, 43]. The homotetramer results in a promiscuous binding site that binds either 
NADPH or DHF [43]. DHF binding is primarily related focused on the pterin ring and the glutamic 
tail is unbound and disordered [43].  
 
The incidence of trimethoprim resistance has been monitored for an extended period in multiple 
countries such as Korea Finland, the UK and France [44, 45]. From its introduction to clinical 
practice in 1962, the incidence of resistance reached was stable until the mid-1980 where there 
was a rapid ~3-fold increase in incidence; the best example being in the town of Rovaniemi, 
Finland trimethoprim resistance was stable at 5% from 1980-1986, then in 1987 resistance spiked 
to 15% [45]. Similarly, in Korea resistance remained stable at 10% until 1996 where rates were 
reported to be 53% [44]. Surveys of trimethoprim resistance have found resistance rates to be 
approaching 70% in developing countries in South America, Asia and Africa [46]. It is very cheap, 
has good results [45].  
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Our current methods of tracking resistance mechanisms limits our ability to capture the full scope 
of what is clinically relevant [45]. Surveillance studies are limited to measuring MIC data and 
looking for the presence of specific resistance genes based on PCR of a set panel of genes. With 
30 DfrA enzymes identified, seven DfrB and a hand-full of genome mutations being implicated in 
resistance, feasibility dictates only a few genes can be monitored for. That being said, studies 
have found that ~96-100% of all trimethoprim resistance is due to the acquisition of DfrA proteins. 
Some are more prevalent than others are. 
 
The wide dissemination of DfrA enzymes in trimethoprim resistance is most likely due to their 
strong association with transposons. Unlike the mutational mechanism of resistance which require 
clonal expansion to become prevalent, horizontal gene transfer results in more stable resistance 
genes and easy sharing of genetic information between bacteria – even between bacterial species 
[45].  In addition to having only minimal fitness costs associated with carrying these genes [13] 
as by a study done in Sweden showed that there was no decrease in the prevalence of these 
genes even after the use of trimethoprim decreased by 85% [47]. 
 
1.4 The Discovery and Development of Propargyl-linked Antifolates  
We have developed a class of DHFR inhibitors designated as propargyl-linked antifolates (PLAs). 
Derived from trimethoprim and optimized through structure-based drug design, these highly 
functionalized inhibitors demonstrate potent activity against Gram-positive and Gram-negative 
pathogens as well as fungal and mycobacterium species [48, 49, 50].  These inhibitors feature a 
6-ethyl-2,4-diaminopyrimidine moiety, the main pharmacophore of these inhibitors, connected to 
either a biaryl or hydrocarbon system through its namesake acetylene linker extended one carbon 
to include a propargylic position. The scaffold can be dissected into three sections: the 
diaminopyrimidine ring and the propargyl linker with opportunities for substitutions at the C6 and 
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propargylic positions and optimization of substituted phenyl and heteroaryl analogs at the B- and 
C-ring positions (Figure 1.5).  
 
Structural data from various species of DHFR demonstrated the addition of a propargyl linker into 
the scaffold of trimethoprim enhanced potency against trimethoprim-sensitive DHFR as well as 
broadened the spectrum of activity to cover trimethoprim-insensitive DHFR. Using this scaffold to 
overcome innate trimethoprim resistance was initially shown through the development of Bacillus 
anthracis DHFR [72]. Crystal structures revealed that binding of the diamino pyrimidine is the 
basis of inhibition and the acetylene linker invokes π-π stacking with a Phe 96 while placing the 
trimethoxybenzyl ring in the hydrophobic substrate binding site [73]. Further structural analysis 
revealed that alkyl substitutions exploit interactions with two hydrophobic residues, Val 32 and 
Leu 29 [73]. Ultimately, it was concluded that bulky substitutions at the meta position of the 
Figure 1.5. The evolution of propargyl-linked antifolates from trimethoprim.  
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trimethoxybenzyl would not only increase contacts with pathogenic targets but also improve 
selectivity over human DHFR. The meta biphenyl PLAs proved successful in this strategy. 
Extensive SAR studies have shown that this current iteration of PLAs allows for optimization of 
high affinity ligands that demonstrate ideal pharmacokinetic properties for lead antibacterial 
agents. 
 
The goal of this project is to optimize this class of DHFR inhibitors against E. coli DHFR while 
being conscious of resistance mechanisms into early in the drug development process. The fact 
that E. coli DHFR undergoes such a significant conformational change presented a unique 
challenge to the structure based drug design process. As the enzyme cycles through multiple 
conformations, inhibitors must be designed such that they can bind the target in varying 
conformational states. A novel approach was taken to develop PLAs to inhibit several clinically 
relevant trimethoprim resistant DHFRs while simultaneously maintaining potent inhibition of the 
enzyme. 
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Chapter 2 Crystal structures reveal propargyl-linked antifolates bind E. coli 
dihydrofolate reductase to form a novel, highly stable inhibitory complex 
 
2.1 Introduction 
Dihydrofolate reductase (DHFR) is an essential enzyme in the folate biosynthetic pathway that 
generates a number of metabolites such as deoxythymidine monophosphate, purine nucleotides 
and amino acids. Rapidly dividing cell rely heavily on products of the folate cycle, as they are 
necessary for DNA repair and replication. Additionally, there are no redundant pathways to the 
reaction that DHFR catalyzes making it an attractive an effective drug target. As such, several 
DHFR inhibitors, such as methotrexate and trimethoprim, are effective treatments for diseases 
characterized by rapidly proliferating cells, such as malignant and infectious disease.  
 
DHFR enzymes from several species have been the subject of detailed structural and mechanistic 
investigations. Interpretations of hundreds of crystal structures and NMR solution structures with 
relaxation data and kinetic enzyme analysis support our current understanding of this critical 
metabolic enzyme [1-3]. Escherichia coli DHFR, a target of trimethoprim, undergoes a unique 
catalytic process that can be exploited to develop inhibitors with a more stable inhibitory complex 
[4]. It has long been known that E. coli DHFR undergoes significant conformational changes in 
order to carry out the catalytic cycle that reduces the substrate, dihydrofolate (DHF), to the 
product, tetrahydrofolate (THF), using the cofactor nicotinamide adenine dinucleotide phosphate 
(NADPH) [5]. Residues in the Met 20 loop (amino acids 9-24) along with those in the F-G loop 
(amino acids 116-132) or the G-H loop (amino acids 142-150) have been shown to be critical in 
the dynamics of E. coli DHFR (Figure 2.1) [21]. These loop regions undergo large structural 
changes when the enzyme switches from an open conformation, during which product is released 
and substrate is bound, to a closed conformation that promotes the chemical reactions of catalysis 
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representing the holoenzyme, transition state and Michaelis complex [6-7]. A third occluded 
conformation occurs later in the catalytic cycle and has been observed in crystal structures with 
product after hydride transfer. In this occluded state, residues from the Met 20 loop occupy the 
cofactor binding site, preventing binding of the nicotinamide ring. Key interactions that stabilize 
the occluded state include hydrogen bonds between Ser 148 and Asn 23 as well as van der Waals 
contacts between Met 16 and Thr 46 or Ser 49 [7].  
 
 
We have been developing propargyl-linked antifolates (PLAs) as antibacterial agents effective 
against Gram-positive and Gram-negative pathogens. These compounds, characterized by a 
diaminopyrimidine ring and alkyne linker, mimic substrate binding and potently inhibit 
Staphylococcus aureus, Bacillus anthracis, Klebsiella pneumoniae and E. coli DHFR [8-11]. Over 
the course of optimizing the affinity of various inhibitors for E. coli DHFR, we determined seven 
crystal structures of different PLAs bound to E. coli DHFR. In contrast to the majority of other 
Figure 2.1. E. coli DHFR is known to go through a major conformational change through its 
catalytic cycle. In the process of cofactor turnover, DHFR moves between an occluded 
conformation consisting of a ternary, closed conformation (b; PDB ID: 1RX2) and binary, 
occluded conformation (c; PBD ID: 1RF7). In each structure, the Met 20 loop (blue), F-G loop 
(red) and G-H loop (green) are highlighted with stabilizing interactions. 
 
34 
 
inhibitor-bound ternary structures in the Protein Data Bank (PDB), five of these models have the 
protein in the occluded state while the other three represent closed state conformations. 
Interestingly, direct interactions between the PLAs and E. coli DHFR residues appear to stabilize 
the occluded state of the enzyme. These contacts are distinct from those reported in structures 
of the enzyme with other ligands.  
 
Because of our findings, a potentially attractive strategy for developing E. coli DHFR inhibitors 
would be to optimize inhibitors that promote and stabilize the occluded state. The presented data 
represents the development of lead compounds designed to inhibit E. coli DHFR through targeted 
interactions with the enzyme. These compounds were designed to directly target residues 
required for enzyme catalysis. In theory, such inhibitors would force the enzyme to replace both 
substrate and cofactor in order to restore activity.  
 
2.2 Results and Discussion 
2.2a Four crystal structures of E. coli DHFR:PLAs reveal the occluded conformation 
As part of a program to optimize PLAs as effective antibacterial agents against E. coli, we carried 
out a structure-based analysis of the binding of several of the PLA ligands to the enzyme. We 
crystallized pure recombinant E. coli DHFR with UCP1029, UCP1037, UCP1195 or UCP1228 
and NADPH (Figure 2.2). Four of these ligands have enzyme inhibition concentration 50 % levels 
(IC50 values) less than 200 nM and the fifth is under 500 nM (Table 2.1).  In addition to the 
diaminopyrimidine, they possess five different scaffolds at the B-ring position: a phenyl (UCP 
1029), a 2,3-benzodioxolane (UCP1037), a 3,4-benzodioxolane (UCP 1195) and a chlorine 
substituted phenyl (UCP1228). These compounds also inhibit the growth of E. coli with MIC 
values ranging from 2.5-20 µg/mL (Table 2.1). 
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Initial crystals with E. coli DHFR bound to UCP1029 and UCP1037 grew in space group P6122 
and diffracted to 2.52 Å and 2.22 Å resolution (Supplemental Table S2.1). The structures were 
solved by molecular replacement using 1RX2 as a model. Omit maps for the ligands and active 
site appear in Supplemental Figure S2. Solved structures show the PLA bound in the folate-
binding portion of the active site as has been observed in all previously reported models of DHFR 
bound to PLAs. These previously observed interactions include hydrogen bonding between the 
diaminopyrimidine ring and Asp 27 as well as the backbone carbonyl of Ile 5. Van der Waals 
interactions between the C6-ethyl substituent and the ring are formed with Phe 31 and Leu 28. 
The propargyl linker forms van der Waals interactions with Ile 94 and Phe 31 and the B-C ring 
system forms hydrophobic interactions with Ile 50, Leu 54, Phe 31 and Leu 28 (Figure 2.2).  
Table 2.1. Enzyme and growth inhibition of select PLAs 
against E. coli DHFR and laboratory strain E. coli 25133. 
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Surprisingly, none of the structures contained the cofactor, NADPH. The original crystallization 
conditions used a two-fold molar excess of NADPH in relation to protein. To rule out the influence 
cofactor concentration might have on crystallization, subsequent crystals were grown with a five-
fold molar excess. 
 
Figure 2.2.  General binding of UCP1029 (a, green), UCP1037 (b, cyan), UCP1195(c, blue) 
and UCP1228 (d, teal). Protein residues and conserved hydrogen bonds are highlighted. 
Residues of the Met 20 loop are in blue. 
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Crystals of UCP1195 and UCP1228 grew in space group P6122 and diffracted to 2.23 Å and 2.10 
Å resolution. Solved structures confirmed that cofactor indeed does not bind in the observed 
complex. Rather, all five structures of E. coli DHFR bound to these PLAs can be classified as 
belonging to the occluded conformation where the Met 20 loop has assumed a position that 
prevents cofactor binding. While the Met 20 loop appears to be dynamic, as its average B-factor 
is 107.02, electron density for the backbone and side chains is clearly observed in the occluded 
position (Figure 2.3). This correlation between a dynamic Met 20 loop and high B-factors has 
been previously observed and may relate to a time-averaged interconversion of the closed and 
occluded forms. 
Figure 2.3. Omit maps focusing residues 9-24 representing the occluded position of the Met 
20 loop. From Left to right: a) E. coli DHFR:1029, b) E. coli DHFR:1037, c) E. coli DHFR:1195 
and d) E. coli DHFR:1228. 
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Previously reported crystal structures of the catalytic cycle capturing the closed and occluded 
state include 1RX4, where E. coli DHFR is bound to dideazafolate and NADP and 1RX7 in which 
E. coli DHFR is bound to folate. These structures establish three hallmarks of the occluded 
conformation: residues Glu 17-Met 20 form a 310 helix as opposed to a β-sheet or hairpin, the 
backbone atoms of Asn 23 and Ser 148 of the G-H loop form strong hydrogen bonds and Met 16 
forms van der Waals contacts with Thr 46 and Ser 49. These three sets of interactions pull the 
Met 20 loop into the nicotinamide binding pocket (Figure 2.4). 
 
The four occluded E. coli DHFR:PLA structures reported here reveal that PLAs form direct 
interactions with the enzyme to stabilize the occluded conformation. Additionally, the standard 
residue-residue interactions that naturally stabilize the occluded conformation are reduced or 
absent when PLAs are bound. PLAs influence the Glu 17 environment to stabilize the occluded 
conformation. The compounds that make additional contacts with Asn 18 demonstrate lower IC50 
values suggesting that further stabilization of the Met 20 loop will lead to more potent E. coli DHFR 
inhibitors. 
 
In the structure of E. coli DHFR bound with folate in the occluded conformation (PDB ID: 1RX7), 
the carboxyl group of Glu 17 forms hydrogen bonds with the carbonyl of Ser 49 and Met 16 abuts 
the α-helix consisting of residues 44-50 making hydrophobic contacts with Thr 46 and Ser 49. In 
structures of PLAs bound to E. coli DHFR, the acetylene-linker orients the sidechain of Glu 17 
into the nicotinamide ring binding site; however, the position of Met 16 is relatively unchanged, 
shifted on average 0.5 Å closer to Thr 46 and Ser 49 (Figure 2.4). 
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Figure 2.4.  Comparison of the occlude conformation observed when E. coli DHFR is 
crystallized with a) DHF to that observed with b) UCP1029, c) UCP1037, d) UCP1195, and e) 
UCP1228. The Met 20 loop (blue) makes unique contacts with PLAs. Rather than the typical 
stabilizing hydrogen bonds between Asp 27 and Ser 148, hydrophobic contacts between the 
inhibitor, Met 16, Glu17, Thr 46 and Ser 49 stabilize the complex. 
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While the occluded state is typically stabilized by hydrogen bonds between Ser 148 and Asn 23, 
the PLA structures do not employ these interactions. In the structure with UCP1029, Asn 23 is 
flipped away from Ser 148 to form a hydrogen bond with Glu 17. In the structure with compound 
UCP1037, the side chain of Asn 23 is flipped away and forms hydrogen bonds with Ala 19 while 
there is a water mediated hydrogen bond between the backbones of Asn 23 and Ser 148. In the 
structure with compound UCP1195, the Asn 23 and Ser 148 are 6 Å apart and the hydrogen bond 
is lost. In the structure with compound UCP1228, Asn 23 forms a backbone hydrogen bond with 
Asp 18 rather than Ser 148 (Figure 2.4).  
 
In ternary structures of E. coli DHFR bound with dideazafolate and NADP, the nicotinamide ring 
of NADPH sits above the pterin ring of folate and makes hydrogen bonds with the amide and 
carbonyl of Ala 7. Interestingly, in structures with UCP1029, UCP1037 and UCP1228 bound, the       
carboxyl group of Glu 17 mimics nicotinamide binding forming water-mediated hydrogen bonds 
with the backbone atoms of Ala 7. Specific to the structure of UCP1195 bound to E. coli DHFR, 
the carboxyl group of Glu 17 forms hydrogen bonds directly to the amide of Ala 7. 
 
While Glu 17 being oriented in the cofactor binding site is a common theme among structures of 
E. coli DHFR bound with PLAs, inhibition appears to be tied to interactions between the ligand 
and Asp 18 (Figure 2.5). In structures if UCP1029, UCP1195 and UCP1228, the amino group of 
Asn 18 makes a series of hydrogen bonds with the amide of Asn 18 and either the hydroxyl or 
carbonyl of Ser 49. The B-rings of UCP1195 and UCP1228 are more functionalized making 
stronger van der Waals contacts with the side chain of Asn 18. The binding potentials of UCP1195 
and UCP1228 with Asn 18 are -2.13 and -2.61 kcal/mol, respectively. The binding potential of 
UCP1029 with Asn 18 is -1.09 kcal/mol. These data correlate with IC50 values; UCP1029 (IC50: 
453 nM) is nearly 4-fold less potent than UCP1195 (IC50: 112nM) and UCP1228 (IC50: 111 nM). 
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UCP1037, with the most potent IC50 of 40 nM, makes a hydrogen bond directly with the amino 
group of Asn 18 through the 2,3-dioxolane functional group, which also makes a water-mediated 
hydrogen bond with the hydroxyl group of Ser 49 and amide of Glu 17. 
 
Figure 2.5. Inhibitor specific interactions with Asn 18. From left to right: a) E. coli 
DHFR:UCP1029, b) E. coli DHFR:UCP1037, c) E. coli DHFR:UCP1195, and d) E. coli DHFR 
DHFR:UCP1228. 
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2.2b Assessing the novelty of PLA interactions 
A detailed survey of crystal structures of E. coli DHFR bound to various ligands (all data taken 
from structures deposited in the PDB) was analyzed to evaluate the novelty of the PLA 
interactions. Supplemental Table S2.3 lists 15 structures, the Met 20 loop classification and typical 
bonds formed for the FG loop and GH loop that stabilize the closed or occluded state. Structures 
of the enzyme in the occluded state include 1RX4 and 1RX7, previously discussed, as well as 
1RG7 that contains methotrexate bound with the loop in a position that is neither in the standard 
occluded or closed conformation. In 1RG7, methotrexate forms extensive interactions with the 
enzyme; however, it has no direct interactions involving the Met 20 loop.  
 
The remaining structures detailed in Supplemental Table S2.3 show that the Met 20 loop is in the 
closed, ternary state and conserved hydrogen bonds that characterize the closed state (Asp 122-
Glu 17, Asp 122-Gly 15, Phe 125-Arg 12, Thr 123-Ile 14) are typically formed in the complexes. 
Among this group of closed, ternary complexes, there are three structures possessing compounds 
with a non-folate scaffold designed for inhibition of the ligand. These compounds form many of 
the same interactions with the enzyme shared with PLAs, but do not form unique interactions with 
the Met 20 loop that alter its conformation. Structure 3KFY is bound to 5-[(4-
chlorophenyl)sulfanyl]quinazoline-2,4- diamine with NADPH and forms hydrogen bonds with Asp 
27 as well as the backbone of Ile 5 and side chain of Thr 113. It also forms hydrophobic 
interactions with Phe 31, Met 20, Ala 7, Thr 46 and Ile 94. Structure 2ANQ reveals that compound 
10a forms hydrogen bonds with Asp 27, Thr 113 and Ser 49 as well as hydrophobic interactions 
with Phe 31, Leu 28, the backbone of Met 20 and Ile 50. The authors specifically point out the 
interactions with Met 20 and Ser 49. Finally, structure 3QYL bound to NADPH and (7S)-7-methyl-
5,6,7,8-tetrahydroquinazoline- 2,4-diamine forms hydrogen bonds with Asp 27 and the backbone 
of Ile 94 as well as hydrophobic interactions with Ile 94, Met 20 and Ile 50. 
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2.2c Preferential inhibition of the closed or occluded conformation 
We acknowledge that crystal packing may influence the closed or occluded loop formation, further 
suggesting that the transition between the occluded and closed states may be facile with a low-
energy barrier. An analysis of crystal contacts for these four structures shows that the symmetry 
mates are far from the relevant loops and do not exert a significant influence on the loop 
conformation. However, upon changing crystallization conditions, we determined the structure of 
E. coli DHFR bound to UCP1145 and NADPH in the closed conformation. In this structure, the 
propargyl linker of UCP1145 forms van der Waals interactions with Met 20, but does not form 
other significant interactions with the Met 20 loop (Figure 2.6).  
 
 
 
Figure 2.6. General PLA binding to E. coli DHFR in the closed conformation portrayed for a-
b) UCP1145, c-d) UCP1195, and e-f) UCPUCP1228. The hydrogen bonds involved in 
stabilizing the closed conformation when the natural substrate is bound is also observed. 
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Interestingly, the compound UCP1145 adopted a different orientation compared PLAs bound in 
the occluded conformation of E. coli DHFR. The PLA scaffold has one stereocenter that dictates 
the biphenyl orientation. In the closed conformation, the enzyme selected the R-enantiomer 
placing the B-ring deeper into the active site. Compared to the occluded structures, the enzyme 
selected the S-enantiomer of PLAs with the B-ring solvent facing (Figure 2.7). Since this could be 
a compound-specific phenomenon, we obtained crystals of E. coli DHFR bound to UCP1195 and 
UCP1228 in the closed state. Like in the structure of UCP1145, closed structures of UCP1195 
and UCP1228 indicate the acetylene linker forms van der Waals interactions with Met 20, but 
does not form other interactions with the Met 20 loop (Figure 2.6). We see the orientation of the 
propargyl methyl dictates the most energetically favorable conformation of the enzyme. When the 
Figure 2.7. E. coli DHFR:UCP1145:NADPH (green) overlay with E. coli DHFR:1195 (gray). 
The ternary structure of E. coli DHFR:UCP1145:NADPH shows a different stereochemistry 
versus the occluded conformation of E. coli DHFR:UCP1195. 
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occluded conformation is formed, the S-enantiomer is present in the active site. Conversely, when 
the closed conformation is formed, the R-enantiomer is seen (Figure 2.8). This observation 
suggests that an equilibrium of conformations may exist in solution. 
 
These findings prompted us to ask which binding mode translates to better enzyme inhibition. We 
generated two E. coli variants based on crystal structure data. In the closed conformation, 
UCP1195 makes major contacts with 13 residues and the cofactor. In the occluded conformation, 
UCP1195 makes major contacts with 14 residues. When in the occluded conformation, UCP1195 
makes contacts with Glu 17 and Asn 18 contributing a total of -9 kcal/mol of van der Waals energy 
(Figure 9; Supplemental Table S2.4). However, when in the closed conformation, Glu 17 and Asn 
18 are shifted 10 Å away from the binding site and the van der Waals contacts are lost. Similarly, 
UCP1228 makes major contacts with 12 residues and the cofactor in the closed conformation and 
15 residues in the occluded conformation. Glu 17 and Asn 18 are equally essential for the 
stabilization of the occluded conformation in UCP1228 structures contributing -11 kcal/mol of van 
Figure 2.8. Structures indicate that enzyme conformation is dependent on the stereochemistry 
for each compound. Left: E. coli DHFR:UCP1195 (occluded-gray) overlay with E. coli 
DHFR:UCP1195:NADPH (closed-blue). Right: E. coli DHFR:UCP1228 (occluded-gray) 
overlay with E. coli DHFR:UCP1228:NADPH (closed-teal). 
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der Waals energy. Then the enzyme is bound with UCP1228 in the closed conformation, Glu 17 
and Asn 18 are shifted 9 Å away from UCP1228 and the van der Waals contacts are lost. 
 
Measuring the Ki of UCP1195 and UCP1228  will provide some insight to the importance each 
whether ligand inhibition is more dependent on a particular enzyme conformation. If the Ki of 
UCP1195 or UCP1228 is higher in the E17A/N18A variant compared to wild-type E. coli DHFR, 
it should indicate that the occluded conformation plays a major role in enzyme inhibition. If activity 
is retained, it should indicate the closed conformation is the primary binding mode. 
 
To assess the impact of E. coli DHFR:NADPH:PLA closed complexes in inhibition, we generated 
the E. coli DHFR M42A/L54A variant. Met 42 and Leu 54 appear to play a more significant role in 
inhibitor binding when the enzyme is in the closed conformation. In closed structures of UCP1195 
and UCP1228, these residues account for a total of -5.7 and -5.2 kcal/mol of van der Waals 
energy, respectively. In occluded structures of UCP1195 and UCP1228, Met 42 and Leu 54 
account for a total of -3.9 and -2.0 kcal/mol of van der Waals energy, respectively (Figure 10; 
Supplemental Table S2.4). Therefore, if compounds lose activity against the M42A/L54A variant 
compared to the wild-type enzyme, it would indicate the closed conformation plays a more 
significant role in enzyme inhibition. If activity is retained, it would indicate that the occluded 
conformation is the major binding mode. 
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Figure 2.9. Comparison of closed and occluded conformations led to the residues selected 
for mutant generation. Glu 17 and Asn18 interact with the ligand in the occluded conformation 
but not the closed conformation (left images). If mutated to Ala 17 and Ala 18 (right images), 
there should be an effect if the occluded conformation is the major binding mode. Top: E. coli 
DHFR:UCP1195(occluded-gray) overlay with E. coli DHFR:UCP1195:NADPH (closed-blue). 
Bottom: E. coli DHFR:UCP1228(occluded-gray) overlay with E. coli DHFR:UCP1228:NADPH 
(closed-teal). 
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 Figure 2.10. Comparison of closed and occluded conformations. Residues selected for mutant 
generation are highlighted. Met 42 and Leu 54 interact with the ligand in the closed 
conformation but not the occluded conformation (left images). If mutated to Ala42 and Ala54 
(right images), there should be an effect if the occluded conformation is the major binding 
mode. Top: E. coli DHFR UCP1195 (occluded-gray) overlay with E. coli 
DHFR:UCP1195:NADPH (closed-blue). Bottom: E. coli DHFR:UCP1228 (occluded-gray) 
overlay with E. coli DHFR:UCP1228:NADPH (closed-teal). 
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2.3 Conclusion 
Crystal structures indicate that PLA are able to bind to E. coli DHFR in both the closed and 
occluded conformations suggesting an equilibrium exists in solution. When bound in the occluded 
conformation, PLAs make unique interactions directly with the Met 20 loop that stabilize the binary 
conformation. Designing inhibitors to optimize interactions with the Met 20 loop should promote 
ligand binding at any point in the catalytic cycle and potentially prolong inhibitor off rate. 
Additionally, data from E. coli DHFR variants should provide details as to which inhibitor complex 
(closed or occluded) is predominate in solution leading to design of stereospecific inhibitors to 
optimize inhibition.  
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2.4 Supplemental Tables & Figures 
Supplemental Table S2.1. Crystallographic data table for E. coli DHFR:PLA structures. 
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Supplemental Figure S2.2. Ligand omit maps. From left to right: a) E. coli DHFR:1029, b) E. coli 
DHFR:1037, c) E. coli DHFR:1195, d) E. coli DHFR:1228, e) E. coli DHFR:1445:NADPH, f) E. 
coli DHFR:UCP1195:NADPH, g) E. coli DHFR:1228:NADPH. 
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Supplemental Table S2.3. Literature review of published E. coli DHFR structures. 
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Supplemental Table S2.4. Calculated Lennard Jones potential (kcal/mol) per each residue to the 
ligand for every structure. 
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Chapter 3 Crystal structures of trimethoprim-resistant DfrA1 rationalize potent inhibition 
by propargyl-linked antifolates 
 
3.1 Introduction 
Infections caused by Gram-negative bacteria are a significant global healthcare threat owing 
primarily to the increasing number of multidrug-resistant strains. Escherichia coli and Klebsiella 
pneumoniae, members of the Enterobacteriaceae family, are often specifically noted for their drug 
resistance, mortality rates and burden on the healthcare system. While there are many 
mechanisms by which these bacteria have become resistant to antibiotics, horizontal gene 
transfer of plasmid-encoded resistance elements is among the most common. The emergence of 
carbapenem-resistant Enterobacteriaceae (CRE) has become a particular concern as these 
bacteria harbor plasmids encoding resistance genes to almost all antibiotics. With the mortality 
rate of patients who contract a CRE bloodstream infection approaching 50 % 
(http://www.cdc.gov/drugresistance/threat-report-2013/), there is a great need for antibiotics 
targeting these bacteria. CRE are defined by the presence of β-lactamases that inactivate 
carbapenems and cephalosporins, which are considered some of the most effective treatments 
for infections caused by Gram-negative bacteria. However, the threat caused by CRE infections 
is increased as the genes encoding carbapenemases and extended spectrum β-lactamases are 
often found on type I and II integrons in conjunction with genes responsible for resistance to 
fluoroquinolones, folate pathway inhibitors and aminoglycosides. As a recent study (1) showed, 
class I integrons are present in 51.1 % of strains and carry recurring resistance genes for a wide 
spectrum of antibiotics including β-lactams, chloramphenicol, trimethoprim, erythromycin, 
aminoglycosides and rifampicin. In fact, it is the multidrug-resistant phenotype associated with 
class I and II integrons that truly defines the threat associated with CRE infections. 
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Inhibitors of the folate pathway, specifically trimethoprim and sulfamethoxazole (TMP/SMX, 
administered as Bactrim®), are used clinically in the treatment of infections caused by E. coli and 
K. pneumoniae. Trimethoprim, an inhibitor of the essential enzyme dihydrofolate reductase 
(DHFR) and sulfamethoxazole, an inhibitor of dihydropteroate synthase (DHPS), have been used 
for decades to effectively treat uncomplicated urinary tract infections and skin and soft tissue 
infections. TMP/SMX has also been successfully used to treat CRE infections (2); however, 
increasing resistance to both agents have limited its use, relegating DHFR and DHPS inhibition 
as an underutilized treatment strategy. In Gram-negative bacteria, trimethoprim resistance has 
increased over the years (3) and now occurs in approximately 30% of all strains (4-8). The primary 
mechanism of this resistance has been the acquisition of trimethoprim-resistant dfr genes 
encoded within integrons.  Two families of extrachromosomal DHFR enzymes, DfrA and DfrB, 
mediate high-level trimethoprim resistance. The DfrA encompasses a family of over 30 
homologous enzymes that maintain 64-88% sequence identity. Within this family of 
extrachromosomal dfr genes, dfrA1 is the most prevalent, accounting for 38 % of dfr-possessing 
strains (9-11). Not only is dfrA1 carried on type I and II integrons, making it a critical mechanism 
of antifolate resistance, it is frequently found in combination with extended spectrum β-
lactamases, metallo-β-lactamases and Klebsiella pneumoniae carbapenemases (12-14). As the 
protein product of dfrA1 is highly resistant to trimethoprim, identification of antifolates that are 
potent inhibitors of DfrA1 would be a significant advancement in overcoming antifolate resistance 
and provide a much needed treatment option for CRE infections. 
 
For several years, we have been developing the class of propargyl-linked antifolates (PLAs) to be 
effective inhibitors of trimethoprim-resistant species of DHFR (15-18). Recently, we reported the 
activity of several of these compounds against K. pneumoniae and we reported the crystal 
structure of K. pneumoniae DHFR (KpDHFR) bound to two PLA compounds (19). Here, we 
60 
 
expand on that work to report that several of the PLAs not only inhibit the wild-type DHFR 
enzymes from Enterobacteriaceae but also significantly inhibit the DfrA1 enzyme as well. We also 
report, for the first time, two high resolution crystal structures of the DfrA1 enzyme. These 
structures of the protein DfrA1 bound to two PLAs are critical for the development of inhibitors 
that are effective against wild-type K. pneumoniae and E. coli as well as DfrA1. 
 
3.2 Results and Discussion 
3.2a PLAs are Effective Antibacterial Agents for Enterobacteriaceae 
As described above, we have been developing the PLAs to be potent antibacterial agents 
targeting wild-type and trimethoprim-resistant Enterobacteriaceae. To examine a number of 
chemotypes that differ in the B and C rings as potential agents that could exhibit broad inhibition, 
we evaluated the antibacterial activity of 11 compounds from our collection against K. 
pneumoniae. Most have good antibacterial activity, with several possessing MIC values at                
1 µg/mL or lower (Table 3.1). We then evaluated several of the compounds, including 
Figure 3.1. Time-kill curves for trimethoprim and compounds 8, 9, 
and 16 against E. coli. 
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trimethoprim, in time-kill assays with E. coli (ATCC 25922) intended to determine whether they 
are bacteriostatic or bactericidal (Figure 3.1). Trimethoprim, as has been shown previously, is 
bacteriostatic against E. coli. Importantly, compounds 8 and 9 show bactericidal properties. In a 
third experiment, we determined that the antibacterial activity results from the inhibition of DHFR 
by performing the MIC evaluation in the presence of 20 µg/mL thymidine, one of the end-products 
of the depleted folate pathway. For the tested compounds (3, 6, and trimethoprim), MIC values in 
the presence of thymidine were all greater than 20 µg/mL, showing that growth inhibition is on-
target. Overall, these experiments show that the compounds penetrate and kill Gram-negative 
bacteria and exhibit on-target inhibition; notably, at least two are bactericidal.  In summary, these 
appear to be promising antibacterial agents. 
 
Table 3.1. Inhibition of DHFR enzymes.  
*N/A: stock was depleted before this evaluation could be completed 
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3.2b Analysis of the DfrA1 enzyme 
A sequence alignment of DHFR enzymes from the chromosomal Gram-negative bacteria E. coli 
and K. pneumoniae, DfrA1 from these bacteria as well as Staphylococcus aureus, a 
representative trimethoprim-sensitive Gram-positive bacterium, (Figure 3.2) shows that the DfrA1 
enzyme shares many conserved domains with other species of DHFR, suggesting that its 
structure is highly homologous. However, it also possesses several residue substitutions that are 
frequently found in other species of trimethoprim-resistant DHFRs. For example, Ile 94 in wild-
type KpDHFR is replaced with a smaller serine residue in DfrA1, which would be predicted to 
have diminished interactions with the methylene bridge of trimethoprim. Additionally, Leu 28 that 
forms van der Waals interactions with the pyrimidine and trimethoxyphenyl rings and is common 
 
Figure 3.2. Structural alignment of the sequences of the wild-type DHFR from E. coli (PDB 
1DRE) (20), K. pneumoniae (PDB ID 4OR7) (19), and Staphylococcus aureus (PDB ID 3SGY) 
(18). The sequences of DfrA1 from E. coli (GenBank ADH82150.1) and DfrA1 from K. 
pneumoniae (GenBank ADH82140.1) are aligned to the DHFR enzymes with structures. 
Active site residues are shown in red. 
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to trimethoprim-sensitive enzymes, is replaced with Gln in the resistant enzymes. Again, this 
substitution is predicted to reduce van der Waals interactions with trimethoprim. Finally, in the 
wild-type enzymes, there is an extra proline residue in the loop comprised of residues 50-54. The 
loss of this proline in the resistant enzymes is expected to reshape the interactions this loop 
typically has with the antifolates. 
 
3.2c Propargyl-linked Antifolates are Active against the A1 Enzyme 
As the PLAs are more highly functionalized than trimethoprim and have been designed to have 
interactions with trimethoprim-resistant enzymes, we expected that several PLAs would be potent 
inhibitors of the DfrA1 enzyme in addition to the wild-type enzymes. Overall, we began by 
screening a number of compounds in our existing library (Table 1: compounds 1-11) that are 
characterized by a diaminopyrimidine substituted at the C6 position, a propargyl linker that may 
be functionalized by a methyl group, a substituted B-ring and a C-ring heterocycle. The C-ring is 
either attached in a meta position relative to the B-ring (compounds 1-7) or a para-position 
(compounds 8-11). Methods for the synthesis of compounds 1, 2 and 6, 7 (17), 3-5 (18) as well 
as 8-11 (21) have been previously published. 
 
Using purified K. pneumoniae DHFR, E. coli DHFR and DfrA1 DHFR in a spectroscopic assay 
that monitors the oxidation of the cofactor, NADPH, we determined 50 % inhibition concentrations 
(IC50 values) for trimethoprim and the PLAs in Table 1. Remarkably, the inhibition data show that 
trimethoprim is ~200- or 1000-fold less potent against the DfrA1 enzyme relative to its value 
against K. pneumoniae or E. coli wild-type DHFR, respectively.  We also found that compounds 
with a benzodioxalane at the B-ring (1 and 2) along with compounds with a simple 2’-methoxy 
phenyl B-ring (specifically 3-6) exhibited relatively potent IC50 values less than 2 µM. Compounds 
with a C-ring in the para-position were generally poor inhibitors of the DfrA1 enzyme. While 
compound 8 has an IC50 value of ~1 µM, compounds 9-11 have IC50 values above 1 µM. In 
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order to explore the active series with additional compounds, we synthesized compounds 12-17, 
extending methods that we have previously published (17, 18, 21). 
 
Excitingly, several of the PLAs are active against both the wild-type and DfrA1 enzymes. For 
example, compound 12 is observed to be 10-fold more potent than trimethoprim against the DfrA1 
enzyme. Replacing the propargylic methyl with a hydrogen (compound 13) increases affinity by 
2-fold.  An ethyl substitution at the C6 position on the diaminopyrimidine ring is responsible for a 
4-fold increase in activity as compared to a hydrogen (compare 14 to 12). Replacing the phenyl 
ring with benzodioxalane (15) and/or replacing the imidazole ring with a pyridyl ring (16) increases 
affinity to the sub-micromolar range. Overall, among this group of inhibitors, compounds 3 and 17 
are the most potent inhibitors with IC50 values of 0.182 and 0.366 µM against the DfrA1 enzyme. 
Strikingly, these compounds do not lose significant activity relative to the K. pneumoniae wild-
type DHFR and exhibit only minor losses relative to the E. coli DHFR. 
 
We also verified that the new compounds have antibacterial activity (Table 3.1), showing that 
many exhibit MIC values less than 1 µg/mL. Compound 16 was selected for evaluation in a time-
kill assay; we confirmed that this inhibitor also shows bactericidal activity (Figure 3.1). In a final 
evaluation, compounds 16 and 17 were shown to be rescued by the presence of 20 µg/mL 
thymidine, demonstrating on-target growth inhibition. 
 
3.2d Crystal structure of DfrA1 
In order to further understand the structure-activity relationships of the PLAs and to promote the 
design of highly potent inhibitors of wild-type and resistant enzymes, we determined high 
resolution crystal structures of DfrA1 bound to NADPH and the two most potent compounds, 3 
and 17. Diffraction data for the crystals were collected at the University of Connecticut and 
Brookhaven National Synchrotron Light Source and extended to 1.95 and 1.87 Å, respectively 
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(crystallography details are found in Supplemental Table 3.1; omit electron density of the ligands 
is shown in Supplemental Figure S3.2).  The crystals belong to space group P3121 and have two 
molecules in the asymmetric unit. Overall, the DfrA1 enzyme adopts the classical DHFR fold with 
an eight-stranded beta-sheet and four flanking alpha-helices. Similar to other ternary structures 
of DHFR, the 2-amino group and N1 of the pyrimidine ring of compound 17 form conserved 
hydrogen bonds with residue Glu 27 and the 4-amino group forms a hydrogen bond with the 
backbone carbonyl oxygen of Met 5 (Figure 3.3a). The nicotinamide group of NADPH forms π-π 
interactions with the propargyl linker, stabilizing the complex. The B- and C-rings form van der 
Waals interactions with Phe 31, Met 50 and Leu 53. In the complex with compound 3 (Figure 
3.3b), the B- and C-rings adopt two different conformations, exploiting two possible pockets in the 
enzyme. Both pockets are defined by the residues Phe 31, Met 50 and Leu 53; however, two 
alternate conformations of Met 50 and Leu 53 are observed, corresponding to the two different 
conformations of the ligand. Additionally, Gln 28 forms a hydrogen bond with the pyridyl nitrogen, 
regardless of the conformation of the biaryl ring system. 
 
The structures of DfrA1 also reveal the basis of resistance to trimethoprim (Figure 3.3c). The 
substitution of Ser 96 in DfrA1 for a bulkier residue (Ile, Leu or Phe) in trimethoprim-sensitive 
enzymes such as wild-type E. coli, K. pneumoniae or S. aureus removes significant van der Waals 
contacts with the methylene bridge. Importantly, Gln 28 in DfrA1 DHFR is usually a hydrophobic 
residue in trimethoprim-sensitive enzymes (eg. Leu); the substitution removes van der Waals 
interactions with both the pyrimidine and trimethoxyphenyl rings and introduces a polar residue in 
a hydrophobic region of the inhibitor. The substitution of Met 50 for the Ile found in trimethoprim-
sensitive enzymes also reduces van der Waals interactions.   
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In one conformation observed in the DfrA1 structure, Met 50 would appear to sterically interfere 
with the trimethoxyphenyl ring, in the other conformation it makes very limited interactions. A 
number of positive interactions that are unique to the PLAs explain much of the potency observed 
against the DfrA1 enzyme relative to trimethoprim (Figures 3.3a and 3.3b). For example, Phe 31 
 
Figure 3.3. Crystal structures of DfrA1 bound to potent inhibitors: a) Crystal structure of DfrA1 
(dark green) bound to compound 17 (light green) with NADPH (salmon) b) Crystal structure of 
DfrA1 (dark blue) bound to compound 3 (magenta) with both conformations shown c) DfrA1 
(dark green) bound to compound 17 (light green) and a model of trimethoprim (gold) d) DfrA1 
(dark green) bound to compound 17  (light green) superimposed with a crystal structure of 
KpDHFR (cyan). Residue differences between the wild-type and resistant enzyme are noted. 
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forms key hydrophobic interactions with the propargyl linker and the C6-ethyl substitution on the 
pyrimidine ring explaining the 4-fold loss in activity upon replacement with a C6-hydrogen. While 
the substitution of Gln 28 is detrimental to trimethoprim binding, the carboxamide forms a 
hydrogen bond with the pyridyl nitrogen of both compounds 3 and 17. A hydrophobic pocket 
consisting of Met 50, Leu 53, Ile 20, and Thr 46 accommodates the dioxalane or phenyl (B-ring) 
as well as the pyridyl or imidazole (C-rings) and their hydrophobic substituents, forming extensive 
van der Waals interactions. 
 
A comparison of the DfrA1 enzyme to wild-type K. pneumoniae (Fig. 3.3d) or E. coli DHFR reveals 
the effects of the residue substitutions on binding PLAs. Conserved interactions between the 
inhibitors and wild-type DHFR or DfrA1 include Phe 31, Thr 46 as well as Ec/Kp Asp 27::A1 Glu 
27 as this does not have a significant effect on binding the pyrimidine ring. The additional 
hydrogen bond formed by Gln 28 in the DfrA1 enzyme explains the greater potency for pyridyl-
containing compounds.  A loop at the active site (Ser 49-Pro 55) is one residue longer in the wild-
type enzyme relative to the DfrA1 enzyme. This insertion alters the interaction of residues 52-53 
from the wild-type or 53 from DfrA1. The residue substitution Ec/Kp Ile 94::A1 Ser 96 removes 
interactions with the propargyl linker, possibly explaining why some of the PLAs lose affinity for 
the DfrA1 enzyme relative to the wild-type. 
 
3.3 Conclusions 
Integrons carrying antibiotic resistance-conferring genes are a major threat for the increased 
spread of resistant Gram-negative bacteria. The most common extrachromosomal DHFR variant 
is DfrA1, which renders trimethoprim ineffective. Here, we present data showing that the 
propargyl-linked antifolates are effective inhibitors of the wild-type and DfrA1 proteins. Crystal 
structures of two of the most potent PLAs with the DfrA1 protein reveal the basis of the affinity of 
the PLAs and the structural origins of the enzyme’s resistance to trimethoprim. The PLAs 
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represent an excellent lead series to develop inhibitors that are potent against wild-type and 
resistant DHFR from Enterobacteriaceae, which may be an important route for overcoming 
antibiotic resistance in these pathogens. 
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3.4 Supplemental Tables & Figures 
Supplemental Table S3.1. Data collection and structure determination statistics. 
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Supplemental Figure S3.2.  Omit electron density of the ligands bound to DfrA1; a) Compound 
17, b) Compound 3. 
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Chapter 4 Structural analysis of trimethoprim-resistant DfrA enzymes leads to multi-
targeting propargyl-linked antifolates 
 
4.1 Introduction 
Clinical success of antibiotic therapy is dependent on two main variables: the diagnosis of (or 
determining the presence of) antibiotic resistance and the availability of effective therapeutics. It 
is well proven that optimization of antibiotic therapy within 6 hours of infection is critical to the 
successful treatment of life-threatening infections [1]. This has become a near impossible task 
given the state of antibiotic resistance. The number of resistance determinants is so overwhelming 
that detecting only a subset of resistance mechanisms provides limited information for picking 
therapeutic agents [3, 4]. With plasmids carrying multiple variants of genes, it is impossible to 
predict which resistant variants will become predominant in the clinic [5]. The ease at which these 
mobile genetic elements spread results in a constantly evolving genetic climate suggesting that 
we are in need for antibiotics that maintain activity indiscriminate of any acquired resistance 
genes. As such, the inability to rapidly diagnosis antibiotic resistance has dictated our strategy for 
drug development. 
 
In 2013, the CDC labelled extended spectrum β-lactamase (ESBL)-producing and 
carbapenemase-producing Enterobacteriaceae (CRE) as an urgent threat to human health [6]. 
Enterobacteriaceae, a family of Gram-negative bacteria that includes Klebsiella pneumoniae and 
Escherichia coli, cause the majority of healthcare-associated infections [7] and are most often 
associated with antibiotic resistance [8,9]. Mortality rates for patients who contract CRE infections 
have been reported to be as high as 52% [10]. Multidrug resistant Enterobacteriaceae was 
assigned the highest threat level because the infections they cause are highly transmissible and 
have a limited number of treatment options [6]. 
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The rapid emergence of multidrug resistant Enterobacteriaceae is often used to illustrate the 
severity of the resistance epidemic. In 2009, a patient from New Delhi, India contracted a urinary 
tract infection caused by K. pneumoniae carrying a novel metallo-β-lactamase [11].In this case, a 
plasmid carrying the blaNDM-1 gene was responsible for conferring resistance to all β-lactams 
including cephalosporins and carabapenems, antibiotics reserved for the most severe infections 
[12]. Since its discovery, strains of Enterobacteriaceae carrying the blaNDM-1 gene have caused 
several outbreaks globally, including but not limited to China, the Netherlands, the United 
Kingdom, Kentucky and New York [13-15]. The genes for carbapenemases are transferred 
between bacteria on mobile genetic elements, such as plasmids, which has contributed to their 
rapid dissemination [5]. Multiple β-lactamase genes can be found on a single plasmid [16-17]. 
Additionally, bacteria can collect multiple plasmids allowing them to express multiple β-lactamase 
isoforms. This represents one of the most challenging aspects of antibiotic discovery. Traditional 
drug discovery focuses on drug optimization against a single target. However, with over 1,600 β-
lactamases identified, it is difficult to individually target and optimize inhibitors in order to keep 
pace with clinical resistance [16-17].  
 
The discovery and development of antibiotics for carbapenemase-producing Enterobacteriaceae 
infections has been marred by discovery void spanning 30 years [18]. Attempts to identify drugs 
with novel mechanisms of action have been counteracted by the inability to find chemotypes able 
to penetrate the cell envelope of Gram-negative bacteria and reach their target [18-20]. Modifying 
current antibiotics to overcome a single molecular mechanism of resistance has been an effective 
strategy [9]. For example, there have been significant efforts to overcome β-lactamase-mediated 
resistance through the design of carbapenemase inhibitors for co-administration with 
carbapenems or modifying β-lactams so they are no longer susceptible inactivation [16]. However, 
these approaches rely heavily on diagnostic capabilities to be clinically useful. A better strategy 
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is to develop a single inhibitor that overcomes the structural and biochemical diversity of multiple 
molecular resistance mechanisms. 
 
Inhibition of the folate pathway has been among the most successful treatment strategies for 
Enterobacteriaceae infections [21]. Trimethoprim, a selective inhibitor of bacterial dihydrofolate 
reductase (DHFR), is one of the most commonly prescribed antibiotics for E. coli  infections [21]. 
However, resistance rates have been reported to be as high 60% [22] severely limiting its use 
and effectiveness. Since its release in 1962, only one new DHFR inhibitor was presented to the 
FDA for approval [22-23]. Iclaprim, currently seeking indications for the treatment of Gram-positive 
infections, was initially denied approval by the FDA in 2009 for failure to show non-inferiority and 
safety concerns [23]. Data also suggests iclaprim is ineffective when trimethoprim-resistant DHFR 
are present (presented below). DHFR clearly represents an underutilized but validated drug 
target. 
 
We have developed a class of DHFR inhibitors, designated as propargyl-linked antifolates (PLAs), 
derived from trimethoprim and optimized through structure-based drug design. These inhibitors 
demonstrate potent activity against Gram-positive pathogens and, as we develop PLAs to include 
Gram-negative coverage, we need to address antifolate resistance early in this process [24-26]. 
Trimethoprim resistance primarily occurs through the acquisition of plasmid-associated dfr genes 
which encode inherently resistant DHFR. dfr genes code for two families of DHFR, DfrA and DfrB 
with DfrA being most clinically relevant [27]. Surveillance studies show that 96% of all 
trimethoprim resistance in Gram-negative bacteria is conferred by the acquisition and expression 
of DfrA enzymes [27-28]. Within the DfrA family, over 30 unique isoforms have been identified; 
five of which account for nearly 85% of all trimethoprim resistance in E. coli: DfrA1, DfrA5, DfrA7, 
DfrA12, DfrA17 [28-31]. As is the case with β-lactamases, a single clinical isolate can accumulate 
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several DfrA isoforms emphasizing that multi-targeting is an essential characteristic of antibiotic 
development [31]. 
 
The ability to bind the same substrate is a common theme of all drug resistant enzymes that can 
be exploited for lead development. In the case of DHFR, the biochemical and structural factors 
that reduce trimethoprim affinity do not alter enzyme function. All DfrA isoforms are able to 
efficiently accommodate the binding and reduction of the natural substrate, dihydrofolate (DHF), 
despite their innate diversity. Design of a pan-DHFR inhibitor should be achievable by simulating 
substrate binding as closely as possible as opposed to designing inhibitors to fit each individual 
target. Shifting the drug design strategy to focus on substrate similarity should produce antibiotics 
that are not only more resilient to resistance but also more clinically applicable.  
 
Towards the development of a pan-DHFR inhibitor, we employed a strategy that incorporates 
substrate envelope constraints in the drug design process. The substrate envelope is made up of 
the 3D space occupied by the substrate and defined by interacting active site residues [32]. It is 
believed that inhibitors with the same binding footprint as the substrate have optimized affinity 
and reduce the deleterious effects of amino acid variations linked to drug resistance. Through the 
use of high resolution crystal structures, we can identify residues that play a role in the loss of 
affinity for inhibitors and residues that are required for substrate binding/turnover. Inhibitors that 
best mimic the substrate’s profile should be able to inhibit all enzymes that bind the substrate. 
Incorporation of the substrate envelope in structure-based drug design has been successful in 
developing HIV protease inhibitors [33-35]. Work from the Schiffer lab demonstrated that 
designing inhibitors to fit within the substrate envelope not only are powerful inhibitors but also 
maintain inhibition in spite of mutational resistance [33-35]. Herein, we present a case study in 
which the substrate-envelope approach to structure-based drug design was applied towards the 
development of pan-DHFR inhibitors. Through application of this technique we were able to 
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explain drug resistance and identify the common active site features that can be exploited for 
inhibition across multiple enzymes.  
 
4.2 Results 
The primary sequences of all known DfrA isoforms were analyzed to infer evolutionary 
relationships and identify structural themes related to trimethoprim resistance and enzyme 
catalysis. The most clinically prevalent proteins, DfrA1, DfrA5, DfrA12 and DfrA17, were 
biochemically characterized to support phylogenic groupings for drug development. Preliminary 
screening of our collection of PLAs revealed several related chemotypes that showed high levels 
of inhibitory potency against E. coli DHFR and two enzymes that best represent the largest group 
of DfrA isoforms, DfrA1 and DfrA5. Crystal structures of UCP1223 and UCP1228 complexed with 
E. coli DHFR, DfrA1 and DfrA5 were determined to define structural features of the substrate 
binding pocket and guide synthesis of pan-DHFR inhibitors. 
 
4.2a Primary sequence analysis of DfrA enzymes 
Phylogenic studies indicate DfrA1, DfrA5, and DfrA17 share an evolutionary history and fall in 
clade of closely related DHFRs consisting of half of all DfrA isoforms (Figure 4.1). DfrA12 forms 
a clade with four Dfr enzymes but still maintain similarity with the DfrA5 clade falling in the same 
branch of the phylogenic tree. The remaining Dfr isoforms split early in the phylogenic tree 
indicating a significantly different sequence origin.  
 
Multiple sequence alignment of the entire DfrA family shows amino acid trends suggesting that, 
while there is a large variation in sequence identity, it is possible to identify structural similarities 
important for successful pan-inhibitor design (Supplemental Figure S4.1). With respect to E. coli 
DHFR (EcDHFR), positions 27 and 28 are restricted to either Asp/Leu or Glu/Gln. Met 20EcDHFR is 
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replaced with a smaller hydrophobic residue in all DfrA enzymes. Ile 94EcDHFR is replaced with a 
Ser or Ala in the major clade of DfrA enzymes. The residues flanking Pro 53EcDHFR also represent 
a major variation between the enzymes. 
Figure 4.1. Multiple sequence alignment of amino acid sequences was done using MUSCLE 
and a phylogenic tree was built off the standard Likelihood Ratio Test for all DfrA isoforms. K. 
pneumoniae DHFR was used as a positive control given the close relation to E. coli DHFR. 
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The global similarity between the four most clinically relevant DfrA isoforms and trimethoprim-
sensitive E. coli DHFR was done using the Expresso mode of T-Coffee (Figure 4.2). Considered 
the most accurate form of multiple sequence alignment, this algorithm builds a template for each 
sequence based on experimentally established structures found in the Protein Data Bank (PDB) 
[36]. Our analysis showed the similarity of E. coli DHFR to the DfrA enzymes ranged between 51-
58%. DfrA enzymes themselves fall into two distinct groups. DfrA1, DfrA5, and DfrA17 are more 
closely related (82-87% similarity) whereas DfrA12 maintains a 51-56% similarity to DfrA1, DfrA5 
and DfrA17 (Figure 4.2). Closer analysis of the amino acid sequences of the trimethoprim-
Figure 4.2. Multiple sequence alignment of the most clinically prevalent DfrA. Pairwise sequence 
alignment was done to determine the similarity between each amino acid sequence; data shown in 
by similarity matrix. Boxed residues interact with the substrate, DHF. Starred residues bind 
trimethoprim. 
 
 
 
 
 EcDHFR DfrA1 DfrA5 DfrA12 DfrA17
EcDHFR 100 55.8 57.7 50.9 56.4
DfrA1 55.8 100 87.3 54.2 85.4
DfrA5 57.7 87.3 100 56.3 81.5
DfrA12 50.9 54.2 56 100 59
DfrA17 56.4 85.4 81.5 59 100
Percent Similarity Matrix (%)
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resistant (TMPR) DHFRs and E. coli DHFR indicate that while the two enzymes share the same 
overall fold and some conserved regions, they have distinct structural differences.  
 
Despite their overall high amino acid sequence homology, E. coli DHFR and the DfrA proteins 
demonstrate variable enzyme kinetic and inhibition profiles (discussed below). One explanation 
may be variations in the DHF binding pocket between E. coli DHFR and TMPR-DHFRs. Residues 
Asp 27EcDHFR, Leu 28EcDHFR, Met 20EcDHFR, Ile 50EcDHFR, Arg 52EcDHFR and Ile 94EcDHFR, allude to a 
different mechanism of catalysis as well as resistance to trimethoprim. In fact, when we compare 
the residues lining the active site of E. coli DHFR to those in DfrA5, they maintain only a 33% 
sequence identity. With these substitutions combined with the loss of Pro 53EcDHFR, the active site 
is anticipated to have a drastically different binding geometry.  
 
As stated previously, amino acid sequence analysis of DfrA1, DfrA5 and DfrA17 indicates these 
enzymes are more closely related when compared to either E. coli DHFR or DfrA12 providing 
insight on potential strategies for development of pan-inhibitors. Active site residues share nearly 
91% identity and those that interact with trimethoprim are 100% conserved.  This not only 
suggests a similar catalytic mechanism for this group but also may also be predictive of a similar 
mechanism of resistance.  
 
The consequences on trimethoprim binding, as demonstrated by a 70-fold loss in affinity (Table 
4.1), can be attributed to particular residue substitutions seen in DfrA1, DfrA5 and DfrA17. 
Specifically, Gln 29DfrA5 aligns with Leu 28EcDHFR Ser 97DfrA5 aligns with Ile 94EcDHFR representing 
the loss of two key hydrophobic interactions required for trimethoprim binding. 
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4.2b Biochemical characterization of E. coli DHFR, DfrA1, DfrA5, DfrA12 and DfrA17 
Recombinant enzymes were expressed and purified to greater than 95% as assessed by SDS-
PAGE. Steady state kinetics were done to substantiate the groupings proposed by 
phylogenic/sequence analysis and also to determine how amino acid sequence variations at 
specific residues contribute to the catalytic properties of these proteins.  All the enzymes follow 
Michaelis–Menten kinetics. Data shows that DfrA enzymes may have a slightly lower affinity for 
DHF in comparison to E. coli DHFR represented by a modest 2-6 fold increase in Km (Table 4.2). 
This is compensated by an equal increase in the rate of catalysis resulting in equally efficient 
enzymes. DfrA5 seems to be a bit of an outlier with a somewhat faster kcat. For this reason, single 
site amino acid substitutions were made to five active site residues in E. coli DHFR to match the 
residues found in DfrA5 to try to understand their role in enzyme function, including how they 
contribute to the substrate envelope and trimethoprim resistance. Ile 5EcDHFR binds the pterin ring 
of DHF. Met 6 is the comparable residues in DfrA1 and DfrA5. I5MEcDHFR no effect on DHF affinity 
 
Table 4.2. Steady-state kinetics of E. coli DHFR, DfrA1 and DfrA5. Select enzyme mutants were 
generated to test the catalytic role of particular residues. 
 
                                                          DHF Steady-State Kinetics  NADPH Steady-State Kinetics 
  
Km 
(µM) R2 
Vmax 
(µM/min/mg) 
kcat 
(s-1) 
kcat/Km 
(µM/s)  
Km 
(µM) R2 
Vmax 
(µM/min/mg) 
kcat 
(s-1) 
kcat/Km 
(µM/s) 
Wild-type enzymes       
 EcDHFR 4.7 ± 0.55 0.97 14.9 4.8 1.0  9.3 ± 2.3 0.93 14.7 4.7 0.51 
 DfrA1 9.7 ± 1.9 0.95 40.8 12.0 1.2  9.3 ± 1.5 0.93 39.6 11.6 1.2 
 DfrA5 24.2 ± 6.6 0.97 102.5 31.8 1.3  19.9 ± 3.1 0.97 110.9 34.4 1.7 
 DfrA12 8.1 ± 1.9 0.93 36.0 11.5 1.4  11.6 ± 1.4 0.99 44.4 14.2 1.2 
 DfrA17 11.0 ± 2.7 0.95 17.8 5.5 0.50  18.8 ± 2.8 0.99 52.7 16.4 0.87 
              
EcDHFR active site variants        
 I5M 6.6 ± 0.99 0.99 4.7 1.5 0.23       
 M20I 3.6 ± 0.89 0.98 16.7 5.4 1.5       
 D27E 6.1 ± 1.8 0.95 24.0 7.7 1.3       
 L28Q 4.2 ± 0.72 0.94 9.4 3.0 0.73       
 I50M 5.4 ± 0.70 0.99 4.2 1.4 0.25       
 I5M/M20I/D27E/I50M 78.8 ± 23.3 0.94 1.1 0.35 0.0044       
               
DfrA5 active site variants         
 E28D 135.8 ± 31.9 0.95 18.3 5.7 0.042       
 Q29L 37.0 ± 6.1 0.99 85.9 26.6 0.72       
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but enzyme efficiency trends toward a 4-fold increase. Met 20EcDHFR makes van der Waals 
contacts with the pterin ring of DHF and the nicotinamide ring of NADPH. Ile 21 is the comparable 
residue in DfrA1, DfrA5, DfrA12 and DfrA17. 
 
M20IEcDHFR exhibited the same substrate binding as wild-type E. coli protein but had faster kcat. 
Asp 27EcDHFR is an important catalytic residue. All DHFRs have an acidic amino acid at this 
position.  Interestingly, 70% of DfrA enzymes have a Glu at this position including DfrA1, DfrA5, 
DfrA12 and DfrA17. Leu 28EcDHFR lines the active site making van der Waals contacts with the 
phenyl ring of DHF. Gln is found at this position in every protein with a D27EEcDHFR substitution 
suggesting they may work cooperatively. Independently, D27EEcDHFR has no effect on substrate 
binding but trends towards an increase in kcat. Likewise, L28QEcDHFR trends to negatively affect 
kcat.  
 
4.2c Crystal structures of E. coli DHFR, DfrA1 and DfrA5 
To better understand the molecular mechanisms behind enhanced inhibition over the panel of 
enzymes, we crystallized E. coli DHFR, DfrA1 and DfrA5 with two potent inhibitors, UCP1223 and 
UCP1228. In total, eight structures were solved enabling us to rationalize the multi-targeting ability 
of these compounds which is recapitulated by enzyme inhibition data. 
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Structures of E. coli DHFR 
Four structures of E. coli DHFR complexed with NADPH and three potent inhibitors (UCP1029, 
UCP1223, and UCP1228) were determined. It has been well-established that E. coli DHFR 
undergoes a major conformational change throughout the catalytic cycle [37]. As substrate and 
cofactor are turned over, E. coli DHFR cycles between a closed (Enzyme:Substrate:Cofactor) and 
occluded (Enzyme:Substrate) conformation defined by the positioning of the Met 20 loop region 
of the protein (Figure 4.3). Three compounds (UCP1029, UCP1223 and UCP1228) were 
crystallized in the occluded conformation. In addition, UCP1228 was crystallized in the closed 
conformation. While PLAs are able to bind in both conformations, the binary complex is believed 
to be the preferred binding mode. Importantly, as will be described below, when compounds are 
bound in the occluded conformation they adopt the same orientation seen in structure of DfrA1 
and DfrA5. Because of this, we only included the binary complex in this analysis.   
Figure 4.3. Structures of E. coli DHFR:UCP1228 reveal two conformations of the enzyme 
bound with inhibitor. Structures of the occluded conformation show UCP1228 is bound in the 
same orientation as structures of DfrA1 and DfrA5. Left: In the occluded conformation, the 
Met 20 loop (blue). Right: In the closed conformation (red), the Met 20 loop accommodates 
the cofactor NADPH (light blue). 
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Diffraction data was collected at SSRL, extending to 2.52 Å (UCP1029; occluded), 1.96 Å 
(UCP1223; occluded), 2.10 Å (UCP1228; occluded) and 1.77 Å (UCP1228; closed). Both crystals 
of E. coli DHFR in the occluded and closed complex contain one molecule in the asymmetric unit 
and belong to the space groups P6122 and P41212, respectively. The occluded conformation 
occurs when DHF is bound and the M20 loop occupies the NADPH binding site (Figure 4.3). As 
shown in Figure 4.4, the PLAs make unique interactions within the active site of the protein. PLAs 
stabilize the occluded state of E. coli DHFR through hydrophobic interactions between the 
propargyl linker and the carbon chain of Glu 17 allowing the amide group to hydrogen bond with 
the backbone nitrogen of Ala 7 as well as with waters in the nicotinamide binding site of NADPH. 
For all three structures of E. coli DHFR bound with PLAs, the B- and C-rings form van der Waals 
interactions with Leu 28, Phe 31, Ile 50 and Leu 54. The diaminopyrimidine ring makes conserved 
hydrogen bonds with Ile 5, Asp 27, and Ile 94.  
 
There are, however, significant differences between the models of E. coli DHFR in complex with 
UCP1029 and UCP1228 owing to the inherent features of the compounds. UCP1228 interacts 
with Met 16, Thr 46, Ile 50, Ile 94 through the propargyl methyl and 2’-chlorine. Lack of B-ring 
functionality dictates how the C-ring is oriented in the active site. The increased flexibility of 
UCP1029 allows the biphenyl system to make stronger contacts with Phe 31, Lys 32 and Leu 54 
(include calculated kcal/mol). Ultimately, it is clear that functionalization of the B-ring corresponds 
to enhanced efficacy as seen by the 4-fold increased inhibition between UCP1029 and UCP1228. 
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Figure 4.4. Figures highlight the residues specific to each ligand. Residues in the Met 20 loop 
(dark blue) are highlighted with a-b) UCP1228, c) UCP1103 or d) UCP1029. Conserved 
interactions include hydrogen-bonding with a water and Ile 5, Asp 27 and Ile 94; hydrophobic 
contacts with Leu 28, Phe 31, Ile 50 and Leu 54. Variations in contacts are seen in residues 
neighboring the B- and C-rings;  Met 16, Thr 46, Ile 50, Ile 94, Lys 32 and Leu 54. 
 
 
a) b)
c) d)
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DfrA1 Structures 
We obtained two structures of DfrA1 complexed with UCP1223 and UCP1228. The crystals 
belong to space group P3121 and contain two molecules in the asymmetric unit that were refined 
separately. The molecules maintain high similarity; RMSD between backbone atoms is 0.211 and 
0.239 for each complex. UCP1223 and UCP1228 maintain conserved hydrogen bonds with Met 
6, Glu 28 and a conserved active site water. Additionally, UCP1223, makes hydrogen bonds with 
Ser 50 and a second active site residue through the 3,4-dioxolane functional group. While both 
compounds make van der Waals contacts with Ile 21, Phe 32, Leu 54 and Met 51, the complexes 
differ where UCP1223 makes contacts with Gln 29 and UCP1228 does not (Figure 4.5).  
 
Figure 4.5. Crystal structures of DfrA1 (cyan) complexed with NAPH (light blue) and a) 
UCP1228 or b) UCP1223. Conserved hydrogen bonding seen with both ligands and residues 
Met 6, Glu 28 and an active site water. Hydrophobic interactions are made between the 
inhibitor and residues Ile 21, Phe 32, Leu 54 and Met 51.  
 
 
a) b)
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DfrA5 Structures 
Crystals of DfrA5 belong to the space group P43 and contain two molecules in the asymmetric 
unit. These molecules maintain a similar overall fold (average backbone atom RMSD = 0.297 and 
0.387). Conserved hydrogen bonds are observed between the diaminopyrimidine ring and 
residues Glu 27 and Met 6. The complex is further stabilized by strong π-π interactions with the 
nicotinamide ring of NADPH and side chain of Phe 32. For both compounds UCP1228 and 
UCP1223, the B- and C-rings make important van der Waals contacts with the α-helix containing 
residues 50-54 (Figure 4.6).  
  
Two conformations of UCP1223 are observed when complexed with DfrA5. Met 51 adopts two 
rotomer conformations to accommodate the corresponding ligand binding position. This 
phenomenon is also seen in previously published DfrA1 structures complexed with PLAs [38]. 
Additionally, one asymmetric unit (chain A of dfrA5_1223) reveals a potentially novel binding 
Figure 4.6. Crystal structures of DfrA5 (green) complexed with NADPH (blue) and a) 
UCP1228 or b) UCP1223. Met 51 adopts two conformations to accommodate two distinct 
conformations of UCP1223. 
 
a) b)
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mode for PLAs where the C-ring interacts with a pocket consisting of His 20, Ile 21, Ser 50 and 
Met 51. Although an energetically accessible orientation, it is noted that crystal symmetry mates 
appear to influence active site residues via lattice contacts such that Gln 29, Lys 33, Leu 54 and 
Arg 57 biasing the structure and, therefore, excluded from this analysis.   
 
4.2d Propargyl-linked inhibition of E. coli DHFR, DfrA1 and DfrA5 
PLAs are considered a promising class of antimicrobial therapeutics for lead development. This 
is not only due to their ability to potently inhibit trimethoprim-sensitive and resistant DHFR but 
also given their proven bactericidal activity [38]. PLAs, characterized by a diaminopyrimidine ring, 
propargyl linker and biaryl system consisting of a substituted B-ring and heterocyclic C-ring, highly 
functionalized PLA scaffolds result in an expanded spectrum of activity. 
 
A subset of 30 PLAs were tested for inhibition of E. coli DHFR, DfrA1 and DfrA5 using purified 
recombinant DHFR in a spectroscopic assay that monitors the oxidation of the cofactor, NADPH 
(Table 4.1)[39]. Known DHFR inhibitors, methotrexate and trimethoprim, in addition to iclaprim, a 
novel DHFR inhibitor in Phase III clinical trials, were included as controls in the screening panel. 
The majority of compounds screened were meta-substituted biphenyl systems. However, we also 
examined novel scaffolds including a sec-B-ring (UCP1103) and para-substituted compounds 
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UCP1044-UCP1045). Synthetic methods and characterizations for compounds included in the 
study were either previously published or developed for this study by the Wright group. 
 
 
Table 4.1. Initial screening of PLAs for inhibition against DfrA1 and DfrA5. 
 
 
 
 
IC50 (µM) 
 
Ki (nM) 
B-ring C-ring C6 Rp Compound EcDHFR DfrA1 DfrA5  EcDHFR DfrA1 DfrA5 fold-spread 
 
- - MTX 0.020 ± 0.002 4.24 ± 0.481 2.90 ± 0.206  1.1 454.1 729.9 638 
 
- - TMP 0.020 ± 0.002 20.2 ± 1.69 2.02 ± 0.062  1.2 2158.9 507.3 1849 
 
- - Iclaprim 0.092 ± 0.005 18.9 ± 0.620 0.508 ± 0.717  5.3 2025.6 127.8 385 
 
 
H CH3 UCP1021 0.083 ± 0.007 0.182 ± 0.005 0.075 ± 0.005  4.8 19.5 18.9 4 
  
Et CH3 UCP1021 0.076 ± 0.005 4.48 ± 0.446 0.177 ± 0.009  4.4 479.2 44.5 110 
 
 
Et CH3 UCP1084 0.018 ± 0.002 2.56 ± 0.206 0.044 ± 0.002  1.1 273.9 11.0 260 
 
 
Et H UCP1091 0.046 ± 0.004 1.12 ± 0.047 0.037 ± 0.004  2.6 120.3 9.3 46 
 
 
H CH3 UCP1092 0.023 ± 0.002 10.2 ± 0.277 0.072 ± 0.008  1.3 1089.9 18.0 841 
  
Et CH3 UCP1102 0.036 ± 0.001 0.826 ± 0.056 0.123 ± 0.010  2.1 88.4 30.9 42 
  
Et CH3 UCP1038 0.031 ± 0.007 0.783 ± 0.020 0.087 ± 0.005  1.8 83.9 22.0 47 
 
 
Et CH3 UCP1037 0.039 ± 0.004 0.366 ± 0.034 0.109 ± 0.007  2.2 39.2 27.4 18 
  
Et CH3 UCP1044 0.101 ± 0.005 0.967 ± 0.031 0.030 ± 0.001  5.8 103.5 7.5 18 
  
Et CH3 UCP1045 0.431 ± 0.040 17.9 ± 0.504 0.178 ± 0.006  24.6 192.5 44.8 8 
 
- - UCP1103 0.055 ± 0.001 1.51 ± 0.234 7.18 ± 0.145  3.1 161.2 1804.8 577 
 
 
Et CH3 UCP1088 0.024 ± 0.004 3.03 ± 0.158 0.025 ± 0.002  1.4 324.4 6.3 232 
 
 
Et CH3 UCP1104 0.186 ± 0.006 4.17 ± 0.898 0.176 ± 0.007  10.7 446.0 44.3 42 
  
Et CH3 UCP1137 0.170 ± 0.011 1.89 ± 0.162 0.041 ± 0.005  9.7 202.8 10.4 21 
  
Et CH3 UCP1145 0.198 ± 0.006 0.113 ± 0.004 0.437 ± 0.040  11.3 12.1 109.8 10 
  
Et CH3 UCP1147 0.145 ± 0.012 0.155 ± 0.011 0.252 ± 0.022  8.3 16.6 63.4 8 
 
 
Et CH3 UCP1164 0.286 ± 0.040 3.19 ± 0.119 0.179 ± 0.020  16.3 341.5 45.0 21 
  
Et CH3 UCP1198 0.192 ± 0.011 0.753 ± 0.065 0.490 ± 0.009  11.0 80.6 123.3 11 
 
 
Et CH3 UCP1212 0.202 ± 0.008 5.24 ± 1.10 0.754 ± 0.016  11.5 560.5 189.6 49 
  
Et CH3 UCP1213 0.122 ± 0.005 0.636 ± 0.100 0.018 ± 0.001  7.0 68.1 4.4 15 
  
Et CH3 UCP1214 0.254 ± 0.027 0.158 ± 0.031 0.058 ± 0.003  14.5 16.9 14.5 1 
  
Et CH3 UCP1219 0.249 ± 0.024 1.57 ± 0.192 0.250 ± 0.025  14.2 168.4 62.9 12 
 
 
Et CH3 UCP1220 0.151 ± 0.013 0.610 ± 0.060 0.125 ± 0.011  8.6 65.3 31.4 8 
  
Et CH3 UCP1221 0.083 ± 0.029 1.79 ± 0.111 0.357 ± 0.043  4.7 192.0 89.8 40 
 
 
Et CH3 UCP1223 0.182 ± 0.029 0.230 ± 0.029 0.086 ± 0.015  10.4 24.6 21.6 2 
  
Et CH3 UCP1225 0.319 ± 0.006 0.331 ± 0.005 0.091 ± 0.002  18.2 35.4 22.9 2 
  
Et CH3 UCP1228 0.111 ± 0.011 0.340 ± 0.032 0.103 ± 0.002  6.3 36.4 25.9 6 
  
Et CH3 UCP1229 0.127 ± 0.019 0.414 ± 0.049 0.290 ± 0.007  7.3 44.3 72.9 10 
 
 
Et CH3 UCP1232 0.183 ± 0.027 1.38 ± 0.057 0.195 ± 0.018  10.5 147.2 49.0 14 
  
Et CH3 UCP1233 0.119 ± 0.027 0.298 ± 0.033 0.073 ± 0.004  6.8 31.9 18.4 5 
  
Et CH3 UCP1239 0.102 ± 0.007 1.19 ± 0.046 0.199 ± 0.017  5.8 127.7 50.0 22 
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DfrA5 enzyme inhibition 
There was a significant loss in activity when the DfrA5 Ki of methotrexate, trimethoprim and 
iclaprim were compared to E. coli DHFR, (664-, 423-, 24-fold, respectively; Table 4.1) While sec-
B-ring (UCP1103 IC50: 7.18 µM) and para-substituted compounds (UCP1224 IC50: 1.73 µM) had 
poor activity against DfrA5, meta-substituted PLAs retained high-level potency. The necessity for 
a propargylic substitution was dependent on the B- and C-ring identity; UCP1084 (IC50: 0.044 µM) 
and UCP1040 (IC50: 0.099 µM) compliment UCP1021 (IC50: 0.182 µM) and UCP1091 (IC50: 0.037 
µM) as pairs of compounds with either a propargyl methyl or hydrogen.  
 
 
 
 
 
IC50 (µM) 
 
Ki (nM) 
B-ring C-ring C6 Rp Compound EcDHFR DfrA1 DfrA5  EcDHFR DfrA1 DfrA5 fold-spread 
 
- - MTX 0.020 ± 0.002 4.24 ± 0.481 2.90 ± 0.206  1.1 454.1 729.9 638 
 
- - TMP 0.020 ± 0.002 20.2 ± 1.69 2.02 ± 0.062  1.2 2158.9 507.3 1849 
 
- - Iclaprim 0.092 ± 0.005 18.9 ± 0.620 0.508 ± 0.717  5.3 2025.6 127.8 385 
 
 
H CH3 UCP1021 0.083 ± 0.007 0.182 ± 0.005 0.075 ± 0.005  4.8 19.5 18.9 4 
  
Et CH3 UCP1021 0.076 ± 0.005 4.48 ± 0.446 0.177 ± 0.009  4.4 479.2 44.5 110 
 
 
Et CH3 UCP1084 0.018 ± 0.002 2.56 ± 0.206 0.044 ± 0.002  1.1 273.9 11.0 260 
 
 
Et H UCP1091 0.046 ± 0.004 1.12 ± 0.047 0.037 ± 0.004  2.6 120.3 9.3 46 
 
 
H CH3 UCP1092 0.023 ± 0.002 10.2 ± 0.277 0.072 ± 0.008  1.3 1089.9 18.0 841 
  
Et CH3 UCP1102 0.036 ± 0.001 0.826 ± 0.056 0.123 ± 0.010  2.1 88.4 30.9 42 
  
Et CH3 UCP1038 0.031 ± 0.007 0.783 ± 0.020 0.087 ± 0.005  1.8 83.9 22.0 47 
 
 
Et CH3 UCP1037 0.039 ± 0.004 0.366 ± 0.034 0.109 ± 0.007  2.2 39.2 27.4 18 
  
Et CH3 UCP1044 0.101 ± 0.005 0.967 ± 0.031 0.030 ± 0.001  5.8 103.5 7.5 18 
  
Et CH3 UCP1045 0.431 ± 0.040 17.9 ± 0.504 0.178 ± 0.006  24.6 192.5 44.8 8 
 
- - UCP1103 0.055 ± 0.001 1.51 ± 0.234 7.18 ± 0.145  3.1 161.2 1804.8 577 
 
 
Et CH3 UCP1088 0.024 ± 0.004 3.03 ± 0.158 0.025 ± 0.002  1.4 324.4 6.3 232 
 
 
Et CH3 UCP1104 0.186 ± 0.006 4.17 ± 0.898 0.176 ± 0.007  10.7 446.0 44.3 42 
  
Et CH3 UCP1137 0.170 ± 0.011 1.89 ± 0.162 0.041 ± 0.005  9.7 202.8 10.4 21 
  
Et CH3 UCP1145 0.198 ± 0.006 0.113 ± 0.004 0.437 ± 0.040  11.3 12.1 109.8 10 
  
Et CH3 UCP1147 0.145 ± 0.012 0.155 ± 0.011 0.252 ± 0.022  8.3 16.6 63.4 8 
 
 
Et CH3 UCP1164 0.286 ± 0.040 3.19 ± 0.119 0.179 ± 0.020  16.3 341.5 45.0 21 
  
Et CH3 UCP1198 0.192 ± 0.011 0.753 ± 0.065 0.490 ± 0.009  11.0 80.6 123.3 11 
 
 
Et CH3 UCP1212 0.202 ± 0.008 5.24 ± 1.10 0.754 ± 0.016  11.5 560.5 189.6 49 
  
Et CH3 UCP1213 0.122 ± 0.005 0.636 ± 0.100 0.018 ± 0.001  7.0 68.1 4.4 15 
  
Et CH3 UCP1214 0.254 ± 0.027 0.158 ± 0.031 0.058 ± 0.003  14.5 16.9 14.5 1 
  
Et CH3 UCP1219 0.249 ± 0.024 1.57 ± 0.192 0.250 ± 0.025  14.2 168.4 62.9 12 
 
 
Et CH3 UCP1220 0.151 ± 0.013 0.610 ± 0.060 0.125 ± 0.011  8.6 65.3 31.4 8 
  
Et CH3 UCP1221 0.083 ± 0.029 1.79 ± 0.111 0.357 ± 0.043  4.7 192.0 89.8 40 
 
 
Et CH3 UCP1223 0.182 ± 0.029 0.230 ± 0.029 0.086 ± 0.015  10.4 24.6 21.6 2 
  
Et CH3 UCP1225 0.319 ± 0.006 0.331 ± 0.005 0.091 ± 0.002  18.2 35.4 22.9 2 
  
Et CH3 UCP1228 0.111 ± 0.011 0.340 ± 0.032 0.103 ± 0.002  6.3 36.4 25.9 6 
  
Et CH3 UCP1229 0.127 ± 0.019 0.414 ± 0.049 0.290 ± 0.007  7.3 44.3 72.9 10 
 
 
Et CH3 UCP1232 0.183 ± 0.027 1.38 ± 0.057 0.195 ± 0.018  10.5 147.2 49.0 14 
  
Et CH3 UCP1233 0.119 ± 0.027 0.298 ± 0.033 0.073 ± 0.004  6.8 31.9 18.4 5 
  
Et CH3 UCP1239 0.102 ± 0.007 1.19 ± 0.046 0.199 ± 0.017  5.8 127.7 50.0 22 
 
 
 
 
IC50 (µM) 
 
Ki (nM) 
B-ring C-ring C6 Rp Compound EcDHFR DfrA1 DfrA5  EcDHFR DfrA1 DfrA5 fold-spread 
 
- - MTX 0.020 ± 0.002 4.24 ± 0.481 2.90 ± 0.206  1.1 454.1 729.9 638 
 
- - TMP 0.020 ± 0.002 20.2 ± 1.69 2.02 ± 0.062  1.2 2158.9 507.3 1849 
 
- - Iclaprim 0.092 ± 0.005 18.9 ± 0.620 0.508 ± 0.717  5.3 2025.6 127.8 385 
 
 
H CH3 UCP1021 0.083 ± 0.007 0.182 ± 0.005 0.075 ± 0.005  4.8 19.5 18.9 4 
  
Et CH3 UCP1021 0.076 ± 0.005 4.48 ± 0.446 0.177 ± 0.009  4.4 479.2 44.5 110 
 
 
Et CH3 UCP1084 0.018 ± 0.002 2.56 ± 0.206 0.044 ± 0.002  1.1 273.9 11.0 260 
 
 
Et H UCP1091 0.046 ± 0.004 1.12 ± 0.047 0.037 ± 0.004  2.6 120.3 9.3 46 
 
 
H CH3 UCP1092 0.023 ± 0.002 10.2 ± 0.277 0.072 ± 0.008  1.3 1089.9 18.0 841 
  
Et CH3 UCP1102 0.036 ± 0.001 0.826 ± 0.056 0.123 ± 0.010  2.1 88.4 30.9 42 
  
Et CH3 UCP1038 0.031 ± 0.007 0.783 ± 0.020 0.087 ± 0.005  1.8 83.9 22.0 47 
 
 
Et CH3 UCP1037 0.039 ± 0.004 0.366 ± 0.034 0.109 ± 0.007  2.2 39.2 27.4 18 
  
Et CH3 UCP1044 0.101 ± 0.005 0.967 ± 0.031 0.030 ± 0.001  5.8 103.5 7.5 18 
  
Et CH3 UCP1045 0.431 ± 0.040 17.9 ± 0.504 0.178 ± 0.006  24.6 192.5 44.8 8 
 
- - UCP1103 0.055 ± 0.001 1.51 ± 0.234 7.18 ± 0.145  3.1 161.2 1804.8 577 
 
 
Et CH3 UCP1088 0.024 ± 0.004 3.03 ± 0.158 0.025 ± 0.002  1.4 324.4 6.3 232 
 
 
Et CH3 UCP1104 0.186 ± 0.006 4.17 ± 0.898 0.176 ± 0.007  10.7 446.0 44.3 42 
  
Et CH3 UCP1137 0.170 ± 0.011 1.89 ± 0.162 0.041 ± 0.005  9.7 202.8 10.4 21 
  
Et CH3 UCP1145 0.198 ± 0.006 0.113 ± 0.004 0.437 ± 0.040  11.3 12.1 109.8 10 
  
Et CH3 UCP1147 0.145 ± 0.012 0.155 ± 0.011 0.252 ± 0.022  8.3 16.6 63.4 8 
 
 
Et CH3 UCP1164 0.286 ± 0.040 3.19 ± 0.119 0.179 ± 0.020  16.3 341.5 45.0 21 
  
Et CH3 UCP1198 0.192 ± 0.011 0.753 ± 0.065 0.490 ± 0.009  11.0 80.6 123.3 11 
 
 
Et CH3 UCP1212 0.202 ± 0.008 5.24 ± 1.10 0.754 ± 0.016  11.5 560.5 189.6 49 
  
Et CH3 UCP1213 0.122 ± 0.005 0.636 ± 0.100 0.018 ± 0.001  7.0 68.1 4.4 15 
  
Et CH3 UCP1214 0.254 ± 0.027 0.158 ± 0.031 0.058 ± 0.003  14.5 16.9 14.5 1 
  
Et CH3 UCP1219 0.249 ± 0.024 1.57 ± 0.192 0.250 ± 0.025  14.2 168.4 62.9 12 
 
 
Et CH3 UCP1220 0.151 ± 0.013 0.610 ± 0.060 0.125 ± 0.011  8.6 65.3 31.4 8 
  
Et CH3 UCP1221 0.083 ± 0.029 1.79 ± 0.111 0.357 ± 0.043  4.7 192.0 89.8 40 
 
 
Et CH3 UCP1223 0.182 ± 0.029 0.230 ± 0.029 0.086 ± 0.015  10.4 24.6 21.6 2 
  
Et CH3 UCP1225 0.319 ± 0.006 0.331 ± 0.005 0.091 ± 0.002  18.2 35.4 22.9 2 
  
Et CH3 UCP1228 0.111 ± 0.011 0.340 ± 0.032 0.103 ± 0.002  6.3 36.4 25.9 6 
  
Et CH3 UCP1229 0.127 ± 0.019 0.414 ± 0.049 0.290 ± 0.007  7.3 44.3 72.9 10 
 
 
Et CH3 UCP1232 0.183 ± 0.027 1.38 ± 0.057 0.195 ± 0.018  10.5 147.2 49.0 14 
  
Et CH3 UCP1233 0.119 ± 0.027 0.298 ± 0.033 0.073 ± 0.004  6.8 31.9 18.4 5 
  
Et CH3 UCP1239 0.102 ± 0.007 1.19 ± 0.046 0.199 ± 0.017  5.8 127.7 50.0 22 
 
94 
 
Pan-DHFR inhibition 
The goal of this program is to develop inhibitors capable of hitting multiple DHFR enzymes. To 
that end, we wanted to analyze compounds that maintained similar inhibition across all three 
enzymes through the fold spread of activity, i.e. the fold change between the highest and lowest 
Ki. To determine molecular mechanisms behind the pan-DHFR inhibition, we crystallized two 
compounds that maintained activity across all three enzymes. UCP1223 and UCP1228 fall in the 
top five compounds that retained potency across enzymes displaying a 3-fold spread of activity. 
By determining what residue-inhibitor interactions are important across the board, we can develop 
inhibitors that exploit these residues improving inhibition for multiple enzymes all at once instead 
of going through the structure-based drug design process for each enzyme individually. 
 
4.3 Discussion 
4.3a Insights to enzyme catalysis: Comparison of E. coli DHFR and DfrA5 
In order for DHFR to convert dihydrofolate (DHF) to tetrahydrofolate (THF), two waters need to 
be oriented near N5 of DHF [40]. These waters are required to protonate N5 and complete product 
formation. In E. coli DHFR, Trp 22 and Asp 27 are responsible for coordinating these waters; 
mutating these residues results in a 4-fold and 73-fold loss in catalytic activity, respectively [40]. 
Trp 22 plays a critical role in catalysis through participation in hydrogen bonding with this water. 
This Trp, position 23 in DfrA5, is conserved across all DHFRs regardless of trimethoprim 
sensitivity. The substitution of Glu 28DfrA5 for Asp 27EcDHFR should have minimal effect on the 
catalytic ability of the enzyme as catalysis is dependent on the ionizability of the residue at this 
position. Glu, equally ionizable as Asp, is also seen in several species of DHFR at this position. 
The longer side chain of Glu might position DHF closer to NAPH promoting faster hydride transfer 
would help explain DfrA5’s 7-fold increase in kcat. 
95 
 
 
In E. coli DHFR, water access to the N5 of DHF is dictated by conformational changes of the M20 
loop and steric hindrance by the side chain of Met 20. In DfrA5, this Met is replaced with Ile – a 
smaller side chain – allowing water to readily access N5 of DHF. Additionally, where E. coli DHFR 
has a Leu at the 28th position, DfrA5 has a Gln (Figure 4.7). The ability of this residue to hydrogen 
bond would facilitate water access to the substrate aiding in product formation, again attributing 
to a kcat of 31.8 s-1. This would suggest a M20I/L28Q E. coli DHFR mutant would increase kcat and 
in DfrA5, I21M/Q29L would decrease kcat. 
 
Figure 4.7. E. coli DHFR bound with folate (PDB: 1RX2) in cyan overlay with a structure of 
DfrA5 docked with THF in green. Trp 30EcDHFR makes a hydrogen bond with water in active 
site. Removal of this functionality is reported to increase the rate of catalysis. The loss of 
hydrogen bonding in DfrA5 (see Leu 31) correlates with a higher kcat. Additionally, a water is 
necessary to protonate the N5 of DHF during catalysis. Met 20EcDHFR blocks access whereas 
Ile 21DfrA5 would not block access. Glu 28 DfrA5 would also stabilize DHF through conversion to 
THF, speeding up catalysis. Leu 28 is the corollary residue in E. coli DHFR.  
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There is a third active site water found in all DHFR structures. In E. coli DHFR, Trp 30, along with 
Ala 6, Tyr 111 and Thr 113, orient this water such that it hydrogen bonds with the 2-amino group 
of DHF. It has been shown that eliminating the hydrogen bonding capabilities of Trp 30 
accelerates catalysis [41]. In DfrA5, Leu is found at this position – a residue with no hydrogen 
bonding capabilities; therefore, results in an increased rate of catalysis compared to E. coli DHFR. 
Extrapolation of this lends to the hypothesis that E. coli DHFR mutants, W30L or W30A, should 
increase kcat and DfrA5 mutants, L31W or L31H, should decrease kcat. 
 
Although a poor marker of affinity, comparison of E. coli DHFR and DfrA5 KmDHF data trends 
towards a loss of substrate affinity. Three residues might contribute to this observation. The 
variation of Ile 94EcDHFR and Ser 97DfrA5 could represent a loss of van der Waals interactions. 
Second, Leu 28EcDHFR is replaced by Gln 29DfrA5 representing in a further loss of van der Waals 
interactions with the substrate. Additionally, Arg 52EcDHFR hydrogen bonds with the glutamic tail of 
DHF; however, Arg 52EcDHFR is replaced by Gly 52DfrA5 disrupting the hydrogen bonding interaction 
between the substrate and the protein. Testing the effects of enzyme variants, L28Q/R52GEcDHFR 
and Q29L/G52RDfrA5, on steady state kinetics would give insight to the significance of these 
observations. 
 
Ultimately, we concluded that while DfrA5 loses hydrophobic interactions with Gln 29DfrA5 when 
compared to Leu 28EcDHFR, the hydrogen bonding capability of Gln 29DfrA5 facilitates faster catalysis 
by aiding in water entry to the active site. Additionally, Ile 21DfrA5 replaces Met 20EcDHFR, effectively 
removing steric hindrance of water access to the active site. These structural differences might 
explain the trends we see in enzyme kinetics between DfrA5 and E. coli DHFR. It appears Gln 
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29DfrA5 is essential to the catalytic activity of TMPR enzymes; stabilization/interaction with this 
residue is necessary to optimize pan-DHFR inhibitors.  
 
4.3b Insights to trimethoprim resistance: DfrA5 
Despite its small size, trimethoprim is a well-recognized tight binding inhibitor of E. coli DHFR [42-
43]. Structures of DfrA5 reveal the basis for trimethoprim resistance and can be summarized by 
three characteristic residue variations. Namely, replacement of Ile 94EcDHFR and Leu 28EcDHFR with 
Gln 29DfrA5 and Ser 97DfrA5 represent a loss of van der Waals interactions with the trimethoxy ring 
of trimethoprim. Additionally, the loss of a Pro, seen at position 53 in E. coli DHFR, causes a 
reorganization of the trimethoprim binding site, specifically, shifting Leu 54DfrA5 out of range of the 
trimethoxy ring (Figure 4.8). 
 
When E. coli DHFR is overlaid with the structure of DfrA5, there are nuanced differences that 
appear to have significant consequences. The Cα of E28DfrA5 is shifted 1.2 Å compared to 
D27EcDHFR moving the diaminopyrimidine ring 0.8 Å. Trimethoprim interacts with Ser 49EcDHFR, Ile 
50EcDHFR, and Leu 54EcDHFR through van der Waals by the trimethoxy ring. The shift imposed by 
Glu 28DfrA5 pulls the trimethoxy ring ~2 Å from the equivalent residues Ser 50DfrA5, Met 51DfrA5, and 
Leu 54DfrA5. 
 
4.3c Propargyl-linked antifolate  inhibition of E. coli DHFR, DfrA1, and DfrA5 
To better understand how PLAs inhibit E. coli DHFR, DfrA1 and DfrA5, the binding potential was 
calculated as Lennard-Jones potential (Supplemental Table 4.2). It was first noted was that 
UCP1228 makes contacts with the same residues as trimethoprim in E. coli DHFR. The acetylic 
linker orients the biphenyl ring system such that it maintains contacts with the pocket consisting 
of Ser 29, Ile 50, and Leu 54. It would seem that the distance between the diaminopyrimidine ring  
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and the B-ring is crucial to maintaining activity in TMPR enzymes [38] especially since 
trimethoprim resistance is associated with reduced interactions in this pocket. As it turns out the 
diaminopyrimidine ring-acetylenic linker occupies the same space – and at the same length – as 
Figure 4.8. a) Trimethoprim (magenta) superimposed in the crystal structure of E. coli DHFR 
(cyan) and 1228 (blue). b) Trimethoprim (magenta) superimposed in crystal structure of DfrA5 
(green) and 1228 (blue). c) Trimethoprim in DfrA5 (green) and E. coli DHFR (cyan) showing 
residue changes and shift of ligand. d) UCP1228 in DfrA5 (green) and E. coli DHFR (cyan) 
showing residue changes. 
 
a) b)
c) d)
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the pterin ring of DHF (Figure 4.9). More closely resembling the substrate suggests this class as 
a whole will maintain potency against TMPR enzymes. Crystal structures support this.    
 
 
Despite high homology, especially within the active site, there is a reduction in PLA inhibition 
between DfrA5 and DfrA1. Although UCP1228 interacts with more residues in DfrA1, when the 
binding potential in calculated in terms of kcal/mol, the sum of these interactions contribute less 
binding potential compared to DfrA5, -54.3 kcal/mol versus -57.0 kcal/mol, respectively 
(Supplemental Table 4.2). The majority of residues that bind UCP1228 tighter in DfrA5, Thr 47, 
Ser 50, Met 51 and Ser 97, are located at the interface of ligand and cofactor binding sites. The 
decrease in interaction strength between DfrA1 and UCP1228 can be attributed to positioning of 
Glu 29 and the diaminopyrimidine ring. The Cα of Glu 29DfrA1 is shifted 0.3 Å compared to Glu 
29DfrA5. This difference has a downstream effect on the position of the biphenyl system; not only 
are B-ring interactions with Thr 47, Ser 50, Met 51, and Ser 97 altered, but the C-ring no longer 
Figure 4.9. The propargyl-linker of PLAs orient the B-ring into position to maintain contacts 
with Ser 29, Ile 50 and Leu 54. The length of this bond mimics the pterin ring of DHF, the 
natural substrate. Trimethoprim, while mimicking DHF via the diaminopyrimidine ring, 
protrudes out of the substrate pocket because the methylene bridge is much shorter. 
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able to interacts with Gln 28 (Figure 4.10). Structure-activity relationships were assed to 
understand the interplay between inhibitors and residues Gln 29, Thr 47, Ser 50, Met 51 and Ser 
97. These residues are conserved throughout TMPR enzymes and appear to play an important 
role in pan-DHFR inhibition. 
 
B-ring structure-activity relationships:  
Interactions with residues Ile 21, Thr 47, Ser 50, Met 51 and Ser 97  
B-ring functionality is critical for pan-DHFR inhibition and can be explained structurally. There is 
a noticeable loss of interactions when we overlay the DfrA1 and DfrA5 crystal structures with 
structures of E. coli DHFR complexed with UCP1029 (lacking B-ring functionality) and UCP1103 
(the B-ring is replaced with a carbon chain). The overlays show complete loss of interactions with 
a pocket consisting of Ser 97, Ile 21, Ser 50, Thr 47 explaining the 27-130 fold loss in activity for 
UCP1103 and 20-fold loss of activity for UCP1029 (Figure 4.11-4.12). 
Figure 4.10. DfrA1 (blue) overlay with DfrA5 (green), both bound with UCP1228.  
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Figure 4.11. Overlays of E. coli:PLA with DfrA1:PLA structures show complete loss of 
interactions with a pocket consisting of Ser 97, Ile 21, Ser 50, Thr 47 when B-ring functionality 
is removed explaining the loss of activity across the resistance enzymes. a-b) E. coli:UCP1103 
(gray) and overlaid with the structure of DfrA1:UCP1228 (cyan) and DfrA1:UCP1223 (blue). 
c-d) E. coli:UCP1029 (magenta) overlaid with the structure of DfrA1:UCP1228 (cyan) and  
DfrA1:UCP1223 (blue). 
 
a) b)
c) d)
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Figure 4.12. Overlays of E. coli DHFR:PLA with DfrA5:PLA structures show complete 
loss of interactions with a pocket consisting of Ser 97, Ile 21, Ser 50, Thr 47 when B-ring 
functionality is removed explaining the loss of activity across the resistance enzymes. a-
b) E. coli DHFR:UCP1103 (gray) and overlaid with the structure of DfrA5:UCP1228 
(green) and DfrA1:UCP1223 (teal). c-d) E. coli DHFR:UCP1029 (magenta) overlaid with 
the structure of DfrA5:UCP1228 (green) and  DfrA1:UCP1223 (teal). 
 
a) b)
c) d)
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We have two series of compounds where the C-ring is maintained as either a pyridine ring or an 
amide substituted benzyl ring (Table 4.4). The para-substituted amide compound UCP1244 
demonstrates poor inhibition of DfrA1 and DfrA5 exhibiting IC50 values of 5 µM and 1.73 µM, 
respectively. The 27- and 9- fold loss of activity from E. coli DHFR is most likely due to 
reorganization of the Met 20 loop and the adjacent α-helix. Meta-substitution, however, enhances 
potency as seen by 15- and 17-fold decrease in IC50 values for UCP1228. Interestingly, replacing 
the 2’-chlorine substitution of UCP1228 with a 2’-methoxy group improves inhibition nearly 2-fold 
against DfrA5 but has no effect on DfrA1 inhibition. 
 
Table 4.4. B-ring SAR analysis. 
 
              
   IC50 (µM)  Ki (nM) 
B-ring C-ring Compound EcDHFR DfrA1 DfrA5  EcDHFR DfrA1 DfrA5 fold-spread 
  
UCP1228 0.111 ± 0.011 0.340 ± 0.032 0.103 ± 0.002  6.3 36.4 25.9 6 
 
 
UCP1226 0.185 ± 0.005 5.00 ± 0.299 1.73 ± 0.096  10.6 535.3 434.7 51 
  
UCP1224 0.191 ± 0.036 0.356 ± 0.016 0.094 ± 0.001  10.9 38.1 23.6 3 
  
UCP1186 0.142 ± 0.011 0.358 ± 0.029 0.102 ± 0.003  8.1 38.3 25.5 5 
 
 
UCP1227 0.225 ± 0.001 1.45 ± 0.046 0.209 ± 0.037  12.9 154.8 52.6 12 
 
 
UCP1244 0.116 ± 0.009 0.804 ± 0.089 0.131 ± 0.005  6.6 86.1 32.9 13 
              
 
 
UCP1167 0.124 ± 0.004 0.037 ± 0.003 0.035 ± 0.002  7.1 4.0 8.8 2 
  
UCP1040 0.169 ± 0.018 4.78 ± 0.410 0.338 ± 0.022  9.7 512.1 84.9 53 
 
 
UCP1037 0.039 ± 0.004 0.366 ± 0.034 0.109 ± 0.007  2.2 39.2 27.4 18 
 
 
UCP1142 0.312 ± 0.023 0.099 ± 0.007 0.069 ± 0.007  17.8 10.5 17.3 2 
  
UCP1142 0.397 ± 0.027 7.25 ± 0.135 1.73 ± 0.081  22.7 776.1 434.5 34 
  
UCP1006 0.031 ± 0.007 0.783 ± 0.020 0.087 ± 0.005  1.8 83.9 22.0 47 
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Further development of the 2’-methoxy group to contain a 2,3-dioxolane  (UCP1226) has no effect 
on DfrA1 activity but a 1.5-fold increase in DfrA5 activity. The IC50 of UCP1227, characterized by 
a 3’-methoxy substitution, decreases by 4- and 3-fold in DfrA1 and DfrA5. The detrimental effects 
of a 3’-substitution is lessened by functionalizing the 4’-position – demonstrated by 2-fold 
improvement in activity across the board in UCP1186. 
 
When we look at each enzyme individually, the pyridine series is on average 1.5 times more 
potent against DfrA5; the reverse trend is true for DfrA1 and E. coli DHFR. Similar to the amide 
series, switching from para-substitution to meta-substitution results in a drastic improvement in 
DfrA1 and DfrA5 activity with a 128- and 10-fold difference in UCP1142 and UCP1167 IC50 values. 
Here, substituting the 2’-chlorine for a 2’methoxy (UCP1040) decreases activity across the board 
by an average of 2.5-fold. Interestingly, the 2,3-dioxolane derivative, UCP1037, resulted in a 4- 
and 2-fold decrease in DfrA1 and DfrA5 activity. The 3’-methoxy had a more profound affect when 
combined with the pyridine C-ring as opposed to the amide-substituted C-ring, seen by the 7.25 
µM and 1.73 µM IC50 values of UCP1006.  
 
Stereochemistry structure-activity relationships 
To analyze the effects of stereochemistry, enantiomerically pure compounds were tested against 
E. coli DHFR, DfrA1 and DfrA5. The preferred stereochemistry for inhibition is dependent on B-
ring functionalization. As with UCP1040, UCP1063 and UCP10064, the 2’-methoxy dictates 
preferential inhibition by the S-enantiomer for all enzymes represented by a 2.5-fold decrease in 
IC50 against E. coli DHFR, a 5-fold decrease against DfrA1, and a 3-fold decrease against DfrA5 
(Table 4.5). Interestingly, the S-enantiomer occupies the active site in the structure of 
DfrA1:UCP1037:NADPH(PDB ID: 5ECC).  
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Analysis of the 3,4-dioxoloane PLAs, UCP1038, UCP1098 and UCP1098, showed that both E. 
coli DHFR and DfrA5 favor the S-enantiomer (UCP1099) by 2-fold and 4-fold, respectively. DfrA5, 
however, preferentially binds the R-enantiomer 4-fold. Perhaps this can be explained by a residue 
variation of Trp 67DfrA5 versus Phe 67DfrA1.  
 
C-ring structure-activity relationships: Optimization of interactions with Gln 29 
Gln 29 is conserved throughout TMPR DHFRs. Given the proposed role Gln 29 plays in catalysis 
and trimethoprim resistance, the inhibitor-Gln 29 interaction could explain pan-DHFR inhibition. 
Data from B-ring structure-activity relationships suggest that optimal binding of PLAs to DHFR is 
co-dependent on both B- and C-ring functionality and not exclusively a function of either. While 
this is true, the C-ring plays a crucial role in inhibition. Comparison of UCP1167 with UCP1228 
shows change of an amide substitution with a pyridine corresponds with a 10-fold increase in 
DfrA1 activity (Table 4.6).  
 
 
Table 4.5. Stereochemistry SAR analysis. 
 
 
   IC50 (µM)  Ki (nM) 
Scaffold Stereochemistry Compound EcDHFR DfrA1 DfrA5  EcDHFR DfrA1 DfrA5 fold-spread 
 
racemic UCP1099 0.031 ± 0.007 0.783 ± 0.020 0.087 ± 0.005  1.8 83.9 22.0 47 
S UCP1038 0.019 ± 0.003 1.716 ± 0.274 0.057 ± 0.004  1.1 183.7 14.4 169 
R UCP1098 0.075 ± 0.005 0.438 ± 0.035 0.115 ± 0.003  4.3 46.9 29.0 11 
              
 
racemic UCP1063 0.312 ± 0.023 0.099 ± 0.007 0.069 ± 0.007  17.8 10.5 17.3 2 
S UCP1040 0.126 ± 0.009 0.346 ± 0.022 0.040 ± 0.002  7.2 37.0 10.1 5 
R UCP1064 0.302 ± 0.018 0.176 ± 0.012 0.109 ± 0.009  17.3 18.8 27.5 2 
              
 
racemic UCP1062 0.397 ± 0.027 7.249 ± 0.135 1.728 ± 0.081  22.7 776.1 434.5 34 
S UCP1006 0.413 ± 0.033 2.307 ± 0.107 0.567 ± 0.031  23.6 247.0 142.6 10 
R UCP1061 0.284 ± 0.058 1.713 ± 0.304 0.367 ± 0.030  16.2 183.4 92.3 11 
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To understand the interactions between the C-ring and DfrA1, we also looked at previously 
reported complexes of DfrA1 with UCP1037 (PDB ID: 5ECX) and UCP1021 (PDB ID:5ECC). The 
greatest change in van der Waals interactions is seen with interactions between Gln 29. In the 
DfrA1:UCP1021 structure, Gln 29 makes direct hydrogen bonds with the pyridine (Figure 4.13). 
The same interaction is observed in the DfrA1:UCP1037 structure. In structures of DfrA1 with 
UCP1223 and UCP1228, the side chain of Gln 29 is oriented away from the ligand explaining the 
trend that pyridine compounds are more effective inhibitors of DfrA1. In structures of DfrA5, the 
amide of UCP1228 stabilizes the complex through a network of hydrogen bonds with Gln 29 and 
Lys 33 explaining the difference in activity between DfrA1 and DfrA5.  
 
Table 4.6. C-ring SAR analysis. 
 
              
   IC50 (µM)  Ki (nM) 
B-ring C-ring Compound EcDHFR DfrA1 DfrA5  EcDHFR DfrA1 DfrA5 fold-spread 
 
 
UCP1186 0.116 ± 0.009 0.804 ± 0.089 0.131 ± 0.005  6.6 86.1 32.9 13 
  
UCP1038 0.031 ± 0.007 0.783 ± 0.020 0.087 ± 0.005  1.8 83.9 22.0 47 
 
 
UCP1223 0.182 ± 0.029 0.230 ± 0.029 0.086 ± 0.015  10.4 24.6 21.6 2 
 
 
UCP1238 0.394 ± 0.022 0.197 ± 0.015 0.062 ± 0.003  22.5 21.1 15.6 1 
              
  
UCP1224 0.142 ± 0.011 0.358 ± 0.029 0.102 ± 0.003  8.1 38.3 25.5 5 
 
 
UCP1040 0.312 ± 0.023 0.099 ± 0.007 0.069 ± 0.007  17.8 10.5 17.3 2 
  
UCP1215 0.228 ± 0.009 0.467 ± 0.032 0.075 ± 0.003  13.0 50.0 18.9 4 
              
  
UCP1228 0.111 ± 0.011 0.340 ± 0.032 0.103 ± 0.002  6.3 36.4 25.9 6 
 
 
UCP1167 0.124 ± 0.004 0.037 ± 0.003 0.035 ± 0.002  7.1 4.0 8.8 2 
  
UCP1256 0.159 ± 0.001 0.065 ± 0.002 0.029 ± 0.003  9.1 6.9 7.2 1 
  
UCP1255 0.169 ± 0.006 0.040 ± 0.003 0.012 ± 0.001  9.7 4.2 3.0 3 
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Data suggests that C-ring optimization is a balance of hydrophobic interactions between the 
carbon chain and hydrogen bonding capabilities with the polar head group of the Gln 29 side 
chain. Structures suggest that a 2’ B-ring substitution orients the C-ring pyridine into an optimal 
position for interaction with Gln 29. As such, UCP1167 and UCP1040 are among the most 
effective inhibitors of TMPR enzymes with IC50 values ranging between 12-99 nM. Conversion of 
the benzyl amine to a tertiary amine also improves inhibition with compound UCP1255’s IC50 
value of 12 nM – the most potent inhibitor we have seen. 
 
4.4 Conclusions 
In summary, propargyl-linked antifolates retain activity across a spectrum of TMPR DHFRs. 
Sequence analysis suggests that a large number of these enzymes are closely related and should 
be susceptible to pan-DHFR inhibition. Crystal structures of E. coli DHFR, DfrA1 and DfrA5 reveal 
the mechanisms of catalysis, trimethoprim resistance and PLA inhibition. Through designing 
inhibitors to optimize the interaction between Gln 29 of DfrA1 and DfrA5, we should be able to 
design and inhibitor effective against the majority of the DfrA family. 
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Figure 4.13. Crystal structures reveal the effects of C-ring variations on interactions with Leu 
54, Lys 33 and Gln 29. a) DfrA1:1037 (magenta). b) DfrA1:1223 (gray). c) DfrA1:1228 (blue). 
d) DfrA1:1021 (teal). e) DfrA5:1228 (green). f) DfrA5:1223 (cyan); observed a hydrogen 
bonding network with Gln 29 via a SO4 – although not believed biologically relevant. 
 
a) b)
c) d)
e) f)
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4.5 Supplemental Tables & Figures 
Supplemental Figure S4.1. Multiple sequence alignment of DfrA isoforms with E. coli DHFR.  
Boxed residues interact with the substrate, DHF. Starred residues bind trimethoprim. 
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Supplemental Table S4.3. The calculated van der Waals binding potential between active site 
residues and compound UCP1228.  
Residue LJP (kcal/mol) Residue LJP (kcal/mol) 
L5 -0.118 L5 -0.116
M6 -2.219 M6 -2.336
V7 -2.748 A7 -2.472
A8 -2.834 A8 -2.857
I9 -0.134 K9 -0.126
I15 -0.193 I15 -0.213
P19 -0.309 P19 -0.220
D20 -0.274 H20 -0.196
I21 -3.464 I21 -3.434
W23 -0.383 W23 -0.399
A25 -0.071 A25 -0.063
G27 -0.050 E28 -0.821
E28 -0.559 Q29 -3.907
Q29 -2.764 L30 -0.187
L30 -0.238 L31 -0.434
L31 -0.501 F32 -9.092
F32 -9.050 K33 -2.285
K33 -2.416 L35 -0.054
I35 -0.068 T36 -0.190
T36 -0.193 L41 -0.146
L41 -0.145 V43 -0.330
V43 -0.224 K46 -0.117
K46 -0.094 T47 -2.270
T47 -1.989 F48 -0.234
F48 -0.218 E49 -0.113
E49 -0.106 S50 -2.135
S50 -2.031 M51 -6.189
M51 -5.511 G52 -0.255
G52 -0.262 L54 -2.587
L54 -2.699 P55 -0.088
P55 -0.096 R57 -0.141
R57 -0.135 Y59 -0.077
Y59 -0.121 I95 -0.085
I95 -0.069 V96 -0.163
V96 -0.104 S97 -2.238
S97 -1.574 G98 -0.464
G98 -0.313 G99 -0.148
G99 -0.115 Y103 -0.831
Y103 -0.761 H114 -0.322
H114 -0.323 I115 -0.186
I115 -0.193 S116 -0.841
S116 -0.892 I118 -0.126
I118 -0.152 Y151 -0.096
Y149 -0.054 NADPH -7.466
Y151 -0.119
NADPH -7.392
Total LJP: -54.280 Total LJP: -57.048
UCP1228 Lennard-Jones Potentials
DfrA1 DfrA5
113 
 
Supplemental Table S4.4. Crystallographic table for reported structures. 
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Supplemental Figure S4.5. Omit maps: a) E. coli DHFR:UCP1103, b) E. coli DHFR:1029, c) E. 
coli DHFR:UCP1223, d) DfrA1:NADPH:UCP1223, e) DfrA5:NADPH:UCP1223, f) E. coli 
DHFR:UCP1228, g) E. coli DHFR:NADPH:UCP1228, h) DfrA1:NADPH:UCP1228, i) 
DfrA5:NADPH:UCP1228. 
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Appendix A Materials & Methods 
Antibacterial activity 
Minimum inhibitory concentrations were determined using K. pneumoniae (ATCC 10031) and the 
microdilution broth assay with an inoculum of 1 x 105 CFU/mL in Isosensitest Broth (Oxoid). 
Growth was monitored at A600 using the Alamar Blue assay; the MIC is defined as the lowest 
concentration of inhibitor to completely inhibit growth. MIC values in the presence of 20 µg/mL 
thymidine were also determined for compounds 3, 6, 16 and 17. 
 
Time-kill curves 
Inocula were prepared from an overnight culture of E. coli 25922 grown at 37˚C in LB media. The 
overnight culture was then adjusted to a 0.5 McFarland standard and diluted to a final 
concentration of ~5 X 105 cfu/mL in IsoSensitest media. Five flasks were prepared: 1 growth 
control (no inhibitor) and 4 inhibitor flasks (trimethoprim and Compounds 8, 9 and 16). Final 
concentrations of inhibitors were made to 4x their respective MIC values. Aliquots from each 
sample were taken at 0, 2, 4, 6, 8, and 12 hours to determine colony counts which were performed 
by making appropriate dilutions in physiological saline and plating 60 µL on pre-warmed LB agar. 
 
Cloning, Expression and Enzyme Purification 
The E. coli DHFR, K. pneumoniae DHFR, DfrA1, DfrA5, DfrA12 and DfrA17 genes were 
synthesized and cloned in the pET41a(+) expression vector containing a C-terminus histidine tag 
by GenScript. Recombinant protein was expressed in E. coli BL21(DE3) cells, purified via nickel 
affinity chromatography and subsequently desalted into 20 mM Tris, 20% glycerol, 0.1 mM EDTA, 
and 2 mM DTT (pH 8.0) using a PD-10 column (GE Healthcare). Protein was concentrated to ~10 
mg/mL, flash frozen with liquid nitrogen and stored at -80 ˚C. 
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Enzyme Kinetics 
Enzyme kinetic parameters were determined from non-linear regression with data generated by 
enzyme activity assays using 12.5−100 μM DHF and 20 μM NADPH for Km and Vmax values (for 
DHF) or 12.5−100 μM NADPH and 50 μM DHF for Km values (for NADPH). All data was analyzed 
using GraphPad. 
 
Enzyme Inhibition Assays 
Enzyme inhibition assays were performed as previously described by monitoring the rate of 
NADPH oxidation by DHFR at an absorbance of 340 nm. Assays were carried out in a buffer 
containing 20 mM TES pH 7.0, 50 mM KCl, 10 mM 2-mercaptoethanol, 0.5 mM EDTA and 1 
mg/mL BSA. Protein (1 mg/mL) was incubated with NADPH (0.1 mM) and inhibitor at 
concentrations near the estimated IC50 for five minutes at 25 ˚C before the reaction was initiated 
with dihydrofolate (0.1 mM). Enzyme inhibition was measured in triplicate and the average IC50 
is reported with standard deviations. 
 
Crystallization 
Preparation of DfrA1 Complexes. DfrA1 DHFR was crystallized using the hanging-drop vapor 
diffusion method. Purified protein (20 mg/mL) was incubated with compound (1 mM) and NADPH 
(2 mM) for 2 hours on ice. An equal volume of protein:ligand:NADPH complex was mixed with the 
optimized crystallization solution consisting of 20 mM imidazole pH 8.5, 300 mM calcium chloride 
and 15 % PEG 6,000. Crystals were observed within 3-5 days at 4 ˚C. Crystals were incubated in 
cryo-protectant buffer containing 15 % glycerol prior to flash-cooling with liquid nitrogen.  
 Preparation of DfrA5 Complexes. DfrA5 DHFR was crystallized using the hanging-drop vapor 
diffusion method. Purified protein (20 mg/mL) was incubated with compound (1 mM) and NADPH 
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(2 mM) for 2 hours on ice. An equal volume of protein:ligand:NADPH complex was mixed with the 
optimized crystallization solution consisting of 100 mM MES pH 6, 500 mM lithium sulfate and 15-
17% PEG 3.3500. Crystals were observed within 3-5 days at 4 ˚C. Crystals were incubated in 
cryo-protectant buffer containing 15 % glycerol prior to flash-cooling with liquid nitrogen. 
Preparation of E. coli DHFR Complexes. Ligand and cofactor [NADPH (Sigma-Aldrich)] was 
added to the apoenzyme with the DHFR concentration at 10 mg/mL.  Following a 2-hour 
incubation period at 4 ˚C, the complex was concentrated to 15-20 mg/mL using Amicon Ultra 
Centrifugal Filters (Millipore). For compounds UCP1029 and UCP1037, a 2-fold molar excess of 
cofactor with respect to DHFR to promote complex formation; whereas, a 5-fold molar excess 
was used for complexes with all other UCP compounds. A 2-fold molar excess of ligand was used 
for all complexes. All crystals were grown using the using the hanging-drop vapor diffusion 
method with EasyXtal DropGruard crystallization plates (Qiagen). The reservoir contained 0.5 mL 
of solution. Equal volumes of DHFR:NADPH:ligand complexes were mixed with optimized 
crystallization solution. Crystals grew within a week of plating at 4 ˚C. Crystals of E. coli DHFR in 
the occlude conformation bound with UCP1029, UCP1037, UCP1195, and UCP1228 grew in 
crystallization solution consisting of 0.3-0.35 M lithium sulfate and 15-19% PEG 6,000. Crystals 
of E. coli DHFR bound with NADPH and UCP1145 grew in 0.4 M ammonium sulfate and 11% 
PEG 10,000. Crystals of E. coli DHFR bound with NADPH and either UCP1195 or UCP1228 grew 
in 0.1 M ammonium phosphate and 30% 2-methyl-2,4-pentanediol. 
 
Data Collection and Refinement 
Diffraction data for E. coli DHFR were collected at Brookhaven NSLS on beamline X25A and the 
data indexed and scaled using HKL 2000. The PHENIX suite was used for the initial molecular 
replacement while structures were refined and validated using non-crystallographic symmetry and 
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structure restraints with the CCP4 software suite. COOT was used throughout the model building 
process. A model of E. coli DHFR in the closed conformation (PDB ID: 1RX2) was initially used 
for the molecular replacement to solve the structure of E. coli bound to UCP1029 for which the 
Met 20 was built in manually. The resulting structure  was subsequently used to probe for the 
structure of E. coli bound to other PLAs. A model of E. coli DHFR in the closed conformation (PDB 
ID: 1RF7) was used in the molecular replacement of E. coli DHFR bound to UCP1145 and 
NADPH. The inhibitor PDB and CIF files were generated with PRODRG. Data collection and 
refinement statistics are reported in Supplemental Table S2.1. 
Diffraction data for DfrA1 bound to were collected at Brookhaven NSLS on beamline X25A and 
the University of Connecticut Protein X-Ray Crystallography Facility on a Rigaku HighFlux 
HomeLab system with either HKL2000 or d*TREK used for indexing and scaling. Structures were 
refined and validated using non-crystallographic symmetry and structure restraints with the 
PHENIX suite while COOT was used throughout the model building process. A model of E. coli 
DHFR (PDB ID: 1RX2) was initially used for the molecular replacement to solve the structure of 
DfrA1 bound to UCP1037 and NADPH, which was subsequently used to probe for the structure 
of DfrA1 bound to remaining PLAs and NADPH. The inhibitor PDB and CIF files were generated 
with PRODRG. Data collection and refinement statistics are reported in Supplemental Tables 
S3.2 and S4.4. 
Diffraction data for DfrA5 bound to PLAs were collected at Brookhaven NSLS on beamline X25A 
and the data indexed and scaled using HKL 2000.  Structures were refined and validated using 
non-crystallographic symmetry and structure restraints with the PHENIX suite while COOT was 
used throughout the model building process. A model of E. coli DHFR (PDB ID: 1RX2) was initially 
used for the molecular replacement to solve the structure of DfrA5 bound to UCP1228 and 
NADPH, which was subsequently used to probe for the structure of DfrA5 bound to UCP1223 and 
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NADPH. The inhibitor PDB and CIF files were generated with PRODRG. Data collection and 
refinement statistics are reported in Supplemental Table S4.4. 
